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GENETIC ALTERATIONS AND CANCER 
 
In general cancer is caused by alterations in the control and activity of genes that 
regulate cellular growth, differentiation, death, adhesion and/or genomic stability. 
Overall, cancer is not caused by a single gene defect. Instead, an accumulation of 
multiple gene defects is required for a normal cell to progress through different 
stages of cancer initiation and progression. Thus, cancer development is a multi-step 
process. The genes involved in this process include so-called proto-oncogenes, 
tumour suppressor genes and genomic stability genes [1]. During tumourigenesis 
proto-oncogenes, which normally stimulate cellular growth, are hyper activated or 
activated under conditions in which the wild-type gene would not be activated. In 
contrast, tumour suppressor genes, normally involved in repression of cellular 
growth, are inactivated. Genomic stability genes, including DNA repair genes, are 
genes that normally limit the amount of genomic alterations. Inactivation of these 
latter genes results in a higher mutation rate in other genes (for example growth 
controlling genes). These gene alterations can occur at the genetic level (see below), 
including somatic and inherited changes and acquired transforming DNA or RNA 
viral sequences, or at the epigenetic level, i.e., DNA methylation, histon modification 
and/or chromatin remodelling [2-4]. Therefore, extensive research has been aimed at 
studying (epi)genetic defects in tumour cells, ranging from cytogenetic research at 
the chromosomal level to molecular research at the basepair level.  
The first tumour-specific chromosomal alteration was detected in 1960, i.e., the 
Philadelphia chromosome in human chronic myeloid leukaemia (CML) [5]. This 
Philadelphia chromosome is the product of a translocation between chromosomes 9 
and 22, leading to disruption and fusion of the ABL and BCR genes, respectively. As 
a result of this fusion, the proto-oncogene ABL is activated. The discovery of this 
gene fusion has led to the development of one of the first effective targeted cancer 
therapies, using imatinib [6]. Imatinib is a tyrosine kinase inhibitor that blocks the 
tyrosine kinase activity of the oncogenic ABL protein. Next to balanced genomic 
changes such as chromosomal translocations, also numerical genomic changes 
resulting from gains or losses of specific chromosomal regions have been implicated 
in tumorigenesis. An explicit example of the latter is gain of chromosome 12p 
sequences in almost all adult testicular germ cell tumours [7]. Gain of (parts of) 12p 
has been suggested to play a role in progression of these tumours [8;9]. However, its 
exact role remains to be established and several candidate genes are currently under 
investigation [reviewed in 10]. Another example of a numerical genomic change is a 
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homozygous deletion within the 10q23 region that led to the discovery of the PTEN 
(MMAC1) gene [11;12]. Loss of function of PTEN appears to be associated with 
advanced stages of multiple human cancers [13] and is associated with two 
hereditary cancer syndromes with overlapping clinical features, i.e., Cowden 
syndrome and Bannayan-Riley-Ruvalcaba syndrome [14].  
Besides somatic chromosomal aberrations, also inherited or constitutional 
chromosomal aberrations have been instrumental for the identification of genes 
involved in the development of various types of cancer. Specific constitutional 
chromosomal deletions, for example, have led to the identification of the RB1 gene in 
retinoblastoma [15-18], the WT1 gene in Wilms’ tumour [18;19] , the VHL gene in 
renal cell cancer [20] and the APC gene in familial adenomatous polyposis [21-24]. In 
addition, inherited or constitutional chromosomal translocations have led to the 
identification of e.g. the FHIT gene in renal cell carcinoma [25], the WAVE3 gene in 
ganglioneuroblastoma [26], the CDC91L1 gene in bladder cancer [27], the ETV6-
NTRK3 fusion gene in fibrosarcoma [28;29], and the NB4S gene in neuroblastoma 
[30].   
These examples clearly illustrate that detailed knowledge on the genetic 
constitution of cells that are associated with tumour development is of major 
importance for the identification of the genes underlying this process. In addition, it 
has been shown that tumour-associated genetic alterations may be used for 
optimizing diagnostic, prognostic and therapeutic protocols. The (still ongoing) 
unravelling of the human genome, both at the sequence content level and at the 
technological level, greatly facilitates cancer research [31;32]. One particular 
technological advance, the development of DNA microarrays, has become invaluable 
for the comprehensive deciphering of cancer cells at both the genome (DNA) and the 
transcriptome (RNA) level [33-35]. 
 
 
GERM CELL DEVELOPMENT 
 
Germ cells are the precursors of sperm and egg cells that are responsible for the 
transmission of genetic information (after meiotic recombination) from one 
generation to the next. During embryonic development the stem cells of the germ cell 
lineage, the primordial germ cells (PGCs), are specified outside the embryo and, 
subsequently, these cells migrate to the site of the future gonads (ovary or testis). The 
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current knowledge on the origin of the germ cell lineage as described below is mostly 
based on mouse studies. 
Development of an embryo from a one cell stage to a fully developed 
organism occurs in several predefined stages. An important stage is the gastrulation 
stage during which the three germinal layers are formed: ectoderm, mesoderm and 
endoderm. Eventually, these layers give rise to the different tissues of the embryo. 
During gastrulation proximal epiblast-derived cells migrate towards the primitive 
streak (Fig. 1A) and extend into the base of the future allantois (Fig. 1B and C) 
[36;37]. These cells are not yet restricted to the germ cell lineage and serve as 
precursors for extra-embryonic mesoderm, allantois and PGCs [38;39]. The first time 
that PGCs can be distinguished from other cell types, indicating that these PGCs are 
indeed germ cell lineage specific, is at the base of the allantois in the yolk sac (Fig. 
1B). From this location the PGCs migrate along the hindgut to the genital ridges, the 
site of the future gonads (Fig. 1D). In case the PGCs arrive at an extragonadal site 
instead of at the genital ridges, they will die by BAX-dependent apoptosis [40].  
Extra-
embryonic 
ectoderm
Visceral 
endoderm
Epiblast
Primitive 
streak 
mesoderm
PosteriorAnterior
Extra-
embryonic 
mesoderm
Primitive 
streak
Allantois
bud
PGCs
PGCs
PGCs
Heart
Foregut Hindgut
Allantois
Yolk sac
Hindgut
Genital 
ridge
Genital 
ridge
A B C D
 
Figure 1. Model for the development and migration route of primordial germ cells in mouse 
embryos, adapted from Hogan et al. [41] and Sadler [42]. The epiblast will produce the embryo; 
extra-embryonic ectoderm and visceral endoderm are supportive tissues. A) Signals from the extra-
embryonic ectoderm induce the proximal epiblast-derived cells to migrate towards the primitive 
streak and become common precursors of extra-embryonic mesoderm, allantois and primordial germ 
cells. B) Restriction to the germ cell lineage of a subgroup from the proximal epiblast-derived cells. 
C) Location of the primordial cells prior to migration into the embryo at the base of the allantois 
within the yolk sac. D) Migration route of the primordial germ cells through the embryo via the 
hindgut (posterior portion of the alimentary tract) into the newly forming genital ridges. 
 
During migration, PGCs proliferate extensively from about 50-100 cells to 
approximately 50,000 cells at two days after entry into the genital ridges [43;44]. 
Shortly before and during the influx of PGCs, the genital ridges differentiate into 
indifferent gonads. Once the PGCs have arrived in the genital ridge, they become 
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non-motile and are called gonocytes. Subsequently they enter the meiotic prophase 
(female gonocytes) or mitotic arrest (male gonocytes). The meiotic entry of the female 
gonocytes (now designated as oocytes) appears to be cell-autonomous as germ cells 
enter the meiotic prophase at about the same time, even if these cells are located 
outside the genital ridge [45]. In contrast, the entry into the spermatogenic pathway 
is induced by SRY, encoded by the Y chromosome, and several other factors [46]. 
Differentiation of the female oocytes is arrested at the last stage of meiotic prophase I 
and does not resume until the time of ovulation. Spermatogenesis, however, does not 
start before puberty and begins with a series of mitotic divisions followed by two 
successive meiotic divisions resulting in the formation of spermatids and 
spermatozoa. Interestingly, the oocyte pathway is considered the default pathway for 
all germ cells [39;45].  
For a long time mammalian germ cells were thought to originate from 
predetermined cytoplasm, similar to germ cells of frogs, flies and worms. However, 
the mammalian germ cell lineage appeared to be induced by external signals from 
neighbouring cells [reviewed in 39]. These external signals include several extra-
embryonic ectoderm-derived factors, such as the bone morphogenetic proteins 
BMP2, BMP4 and BMP8B [47-49]. During the processes of germ cell specification, 
migration and homing to the genital ridges many additional factors are involved that 
are either expressed by the (primordial) germ cells themselves or by their 
neighbouring cells. Several of these factors are currently under investigation 
[39;50;51]. 
 
 
HUMAN GERM CELL TUMOURS 
 
The neoplastic counterparts of human germ cells are the human germ cell tumours 
(GCTs). These tumours constitute a heterogeneous group of neoplasms that can 
develop at any age, in both sexes, in the gonads and at several extragonadal sites 
along the midline of the body. Also, the clinical outcomes of GCTs are diverse, 
ranging from benign teratomas to highly malignant and clinically aggressive 
tumours such as embryonal carcinomas and choriocarcinomas. Phenotypically, one 
or more structures that appear during embryonic development are represented in 
these tumours with their germ cell (seminomas), embryonic (teratomas, embryonal 
carcinomas) and extra-embryonic (choriocarcinomas, yolk sac tumours) 
morphologies. 
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Based on anatomical location, phenotype, age, and genotype the GCTs can be 
divided into five types: type I GCTs existing of teratomas and yolk sac tumours that 
primarily occur in neonates and infants, type II GCTs occurring as seminomatous 
and non-seminomatous GCTs; the seminomatous tumours are called seminomas in 
the testis, dysgerminomas in the ovary or dysgenetic gonads and germinomas in the 
brain, type III GCTs, the spermatocytic seminomas in elderly men, type IV GCTs, the 
dermoid cysts (mature cystic teratomas) of the ovary, and, recently added to this list, 
type V GCTs, the hydatidiform mole of the placenta/uterus [10] (Table 1).  
The recurrence risk of type I GCTs depends on primary site (with the 
coccygeal tumours being most at risk), histological grade, and completeness of the 
primary resection including the adjacent organ of origin (coccyx, ovary, testis etc.) 
[52;53]. The mature teratomas in this group are mostly benign and can be cured by 
surgery alone, however incomplete resection of teratomas imposes a risk for relapse 
[52]. In contrast to most metastatic cancers, metastatic testicular GCTs (TGCTs, type 
II) exhibit a high cure rate. Over 80% of patients with a metastatic TGCT can be cured 
using cisplatin-based combination chemotherapy [54]. Even when the tumour is 
spread to distant organs (such as lung) 74% of the TGCT patients have a 5-year 
survival rate [55]. Most spermatocytic seminomas (type III) and dermoid cysts (type 
IV) can be cured by resection.  
Chromosomal aberrations have frequently been found in GCTs (Table 1). For 
the adult testicular type II GCTs for example, gross numerical and structural 
abnormalities have been described by several groups [56-58]. In addition, these 
tumours show a consistent gain of 12p, either via the generation of one or more 
copies of an i(12p) chromosome or via alternative ways, including high copy number 
amplifications of defined regions of 12p [57-63], reviewed in [7]. Due to the low 
incidence of spermatocytic seminomas, these tumours are not very well characterised 
at the cytogenetic level. The few spermatocytic seminomas that have been examined 
(type III) were mainly aneuploid [64;65]. In addition, one study showed recurrent 
gains of chromosome 9, suggesting that this aberration may be characteristic for this 
latter subgroup [65]. Karyotypes from dermoid cysts of the ovary range from diploid, 
diploid/tetraploid to near triploid [66;67]. 
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Table 1. Characteristics of the five germ cell tumour types 
Type Anatomical location Phenotype Originating cell Age  DNA ploidy
I testis/ ovary/ sacral 
region/ 
retroperitoneum/ 
mediastinum/ neck/ 
midline brain/ other rare 
sites
(immature) 
teratoma/ yolk 
sac tumour
early PGC/ 
gonocyte
neonates and 
infants
teratoma: diploid,      
yolk sac tumour: 
aneuploid
II testis seminoma/         
non-seminoma
early PGC/ 
gonocyte
>15 years Aneuploid (+/- 
triploid)
ovary dysgerminoma/   
non-seminoma
early PGC/ 
gonocyte
> 4 years aneuploid
dysgenetic gonad dysgerminoma/   
non-seminoma
early PGC/ 
gonocyte
congenital diploid/tetraploid
anterior mediastinum 
(thymus)
seminoma/         
non-seminoma
early PGC/ 
gonocyte
adolescents diploid/tri-tetraploid
midline brain (pineal 
gland/hypothalamus)
germinoma/       
non-seminoma
early PGC/ 
gonocyte
children (median 
age 13 years)
diploid/tri-tetraploid
III testis spermatocytic 
seminoma
spermatogonium/ 
spermatocyte
> 50 years aneuploid
IV ovary dermoid cyst oogonia/ oocyte children/adults (near) diploid, 
diploid/tetraploid, 
~triploid
V placenta/uterus hydatidiform 
mole
empty ovum/ 
spermatozoa
fertile period diploid
 
Adapted from Oosterhuis and Looijenga [10] 
 
 
GERM CELL TUMOURS IN NEONATES AND INFANTS  
 
This thesis focuses on the type I GCTs of neonates and infants that comprises the 
predominantly benign teratomas and their malignant counterparts, the yolk sac 
tumours. The incidence of these type I GCTs is about 0.12 per 100,000 [68]. GCTs of 
neonates and infants differ in many aspects from the adult and elderly GCTs and it 
has been suggested [67;69-71] that they may constitute a separate pathogenetic 
subgroup based on site of occurrence, histology, clinical behaviour, cell of origin, and 
cytogenetics.  
 
Occurrence and histology of infantile GCTs  
The majority of GCTs that occur under the age of 5 years develop at extragonadal 
sites, whereas more than 90% of GCT in adults develop in the gonads [53;70;72]. The 
most common extragonadal site for type I GCTs is the sacrococcygeal region [70]. 
The site of occurrence is dependent on age as well as on histology. Teratomas, for 
example, present as sacrococcygeal tumours at birth, whereas later in life they are 
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mainly present as gonadal tumours. In the ovaries teratomas predominantly occur 
between the ages of 9 to 15 years. 
Also at the histological level adult GCTs and infantile GCTs are distinct. 
Infantile GCTs mostly present as teratomas or yolk sac tumours (YSTs) [72-75], 
whereas adult GCTs mostly present as seminomas or non-seminomas. Interestingly, 
these non-seminomas can also contain teratoma and/or yolk sac tumour 
components. Genetically however, these components are quite different from their 
infantile histological counterparts, as they are predominantly aneuploid and 
typically contain a marker chromosome: i(12p). A study of 780 children (<15 years) 
with GCTs showed that age is a critical factor for the type of histology [52]. In this 
cohort the median age of children with a teratoma was 5 months (n=329). After the 
age of 5 months the main histology is shifted to YSTs with a median age of 2 years 
(n=260). Embryonal carcinomas, seminoma-like tumours and choriocarcinomas occur 
mainly later in life, after the age of 8 years. These observations were confirmed in an 
additional study of 1,157 childhood GCTs (<15 years) [70]. 
Type I teratomas may give rise to secondary malignancies [76]. Specifically, 
immature teratomas of the sacral region and the neck have been reported to recur as 
YST [72;77-79]. This notion is supported by animal models, i.e., the occurrence of 
teratomas and the recurrence of YSTs has also been reported in mice [80-82]. Based 
on observations that YSTs may be aneuploid and teratomas may be diploid (see 
below), the development of immature teratomas into YSTs is suggested to be 
accompanied by cytogenetic changes [83;84].  
 
The cell of origin: different for infantile and adult GCTs? 
The term germ cell tumour implies that all subtypes develop from a common 
precursor cell. So far, this cell is thought to be the primordial germ cell (PGC). The 
occurrence of extragonadal GCTs may be explained by an aberrant migration pattern 
of PGCs during embryogenesis [85-87]. It cannot be excluded, however, that these 
cells may have a function at these extragonadal sites. The germ cell origin of some of 
the GCT subtypes is supported by the expression of the germ line-specific protein 
VASA or their specific pattern of genomic imprinting [10;88-91] (see below). In 
addition, these studies suggested that the different subtypes may not originate from 
a common precursor cell, but from germ cells of different developmental stages.  
Studies on the DNA content of infantile GCTs and adult TGCTs suggest that 
these two tumour types may have a different precursor cell. Adult TGCTs are usually 
aneuploid, with overall differences between non-seminomas and seminomas. 
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Seminomas appear to be hypertriploid to tetraploid, whereas non-seminomas appear 
to be in the hypotriploid to peritriploid range (reviewed in [57;84;92;93]). Infantile 
sacral teratomas were found to be diploid, independent of the grade of immaturity 
[74;84;94]. Infantile YST were found to be aneuploid, although also diploid cases 
have been reported [74;95;96].  
Next to ploidy differences between infantile and adult GCTs, there is also a 
disparity in the presence of carcinoma in situ (CIS) in these tumours. For adult 
TGCTs, CIS lesions are believed to provide the precursor cells [97-99]. For the other 
subtypes, however, this scenario has been questioned. Except for some isolated 
reports [100-102], infantile GCTs do not appear to be associated with CIS, at least not 
at a morphological level [103-105]. This again implies a difference in origin between 
adult and infantile types of GCT.  
Recently, Schneider et al. [88] reported a multipoint imprinting analysis of 
gonadal and extragonadal infantile GCTs. The term imprinting indicates that alleles 
of paternal and maternal origin are differentially expressed. The inherited imprinting 
status is erased in PGCs, supposedly during the migration from the yolk sac to the 
genital ridges, and may be imparted before they enter meiosis (reviewed in [106]). 
However, the exact time frame in which this occurs is not yet known. Schneider et al 
[88] determined the imprinting status of three well-known imprinted genes, H19, 
IGF-2 and SNRPN in a group of 42 infantile GCTs. By doing so, they deduced 
whether the cell of origin is a PGC before the entry into the genital ridges (PGC has 
the imprinting status of the original cell), or a premeiotic PGC with an erased 
imprinting status, which is measured by a biallelic expression of H19 and IGF-2 and 
no methylation of the imprinting control region (ICR) of the H19 or the SNRPN genes 
(loss of imprinting (LOI) of H19, IGF-2 and SNRPN). The SNRPN alleles turned out to 
be unmethylated in both gonadal and extragonadal infantile GCTs. In addition, 
gonadal and extragonadal infantile GCTs showed similar but lower frequencies of 
LOI of the H19 and IGF-2 genes [88;107] as compared with adult TGCTs [90]. Because 
the imprinting pattern of the latter genes differed between the infantile and adult 
GCTs, they suggested that initiation of at least some infantile GCTs may occur 
during germ cell migration, whereas the initiation of adult GCTs may occur at later 
stages of PGC development. Another possibility is that failure to erase the H19 and 
IGF-2 imprinting status during PGC migration may in fact reflect an early step in 
tumorigenesis.  
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The differences in cell of origin and genomic imprinting pattern between the 
different germ cell tumour subtypes were recently reviewed by Oosterhuis and 
Looijenga [10] (Table 1). They suggested as cell of origin an early PGC/gonocyte for 
the type I tumours (with a biparental, partially erased imprinting pattern), a 
PGC/gonocyte for the type II tumours (with an erased imprinting pattern), a 
spermatogonium/spermatocyte for the type III tumours (with a partial paternal 
imprinting pattern) and an oogonium/oocyte for the type IV tumours (with a partial 
maternal imprinting pattern). 
 
Recurrent chromosomal aberrations in infantile GCTs  
Next to the recurrent presence of an i(12p) marker chromosome and gain of parts of 
12p in gonadal and extragonadal type II TGCTs, other frequent chromosomal 
aberrations have been encountered, such as specific gains for the chromosomes 7, 8, 
12, and X and specific losses for the chromosomes 11, 13, 18, and Y [92;108;109], 
reviewed in [7;58]. For infantile GCTs the overall cytogenetic picture is different 
although these tumours have not been studied as extensively as the type II GCTs. 
The i(12p) marker chromosome is not a common feature in infantile GCTs and 
specific gains and losses as described for adult TGCTs are rare. Instead, the most 
prevalent chromosomal aberrations found in infantile GCTs are losses of 1p (more 
specific: 1p36) and 6q [69;71;79;95;110-115]. In addition, abnormalities of 
chromosome 3 (mainly gain of 3p), gains of 1q and 20q have been described as 
recurrent aberrations, as well as losses of (parts of) chromosome 4 
[69;79;88;95;113;115;116]. All these aberrations were detected in malignant infantile 
GCTs, mainly YSTs with or without a teratoma component. Loss of 1p and loss of 6q 
have also been detected in several cases of adult TGCT. These losses were found in a 
lower frequency as compared to the infantile GCTs and they were observed mostly 
in non-seminomas, especially in tumours containing YST or embryonal carcinoma 
(EC) components [58;109;117-120]. Bussey et al. [111] suggested that loss of 1p is 
related to malignancy independent of the age of the patient. However, in their study 
most patients under the age of 5 years had teratomas and only a few had YSTs or a 
mixed tumour of YST and teratoma. So far, most chromosomal aberrations of 
infantile patients have been detected in the YST components. The observation that 1p 
and 6q losses occur in infantile GCTs with a YST component and that these losses 
occur in adult TGCTs containing YST or EC components, suggests that these 
anomalies may be related to the biological behaviour of these malignant tumour 
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(sub)types. This phenomenon may be related to age as most 1p and 6q losses are 
observed in YSTs of infants.  
In contrast to the YSTs, most studies of benign infantile teratomas have 
indicated that they are diploid with normal karyotypes. In addition, in a classical 
CGH study using microdissected teratoma material no chromosomal imbalances 
were found. This latter observation may indicate that the absence of chromosomal 
aberrations in the cytogenetic studies is not due to cell culture artefacts [79]. Still, 
genetic aberrations may be too small to be detected with classical CGH or 
karyotyping methods. In a few cases, however, chromosomal aberrations were 
detected, including 1q abnormalities [121-124]. It is unknown whether these 
teratomas also contained YST components. 
 
 
OBJECTIVES  
 
In comparison with the most prevalent type of GCTs, i.e., TGCT of type II, 
information on the genetic constitution of the type I GCTs has remained scarce so far. 
The overall objectives of this thesis were to identify candidate genes that play a role 
in one or more of the developmental stages of type I GCTs and to identify 
chromosomal anomalies that may be used as diagnostic/prognostic markers for type 
I GCTs. Therefore, two approaches were employed: (1) positional cloning of two 
constitutional chromosome translocations in patients with type I GCTs and (2) 
genomic microarray analysis of acquired chromosomal aberrations in a selected 
group of sporadic type I GCTs. 
The two constitutional chromosome translocations studied in this thesis, 
t(12;15)(q13;q25) and t(8;12)(q23;q12), are of particular interest since they both exhibit 
breakpoints in 12q11-q13, a suggested region with candidate genes for the 
development of human GCTs [116;117;123]. The motive for studying these two 
translocations was the initial mapping of both chromosome 12 breakpoints to the 
12q13 region, suggesting that these breakpoints may disrupt the same gene within 
this region. The positional cloning of the respective translocation breakpoints and the 
identification of its corresponding genes are described in chapters 2, 3, and 4. 
Microarray-based comparative genomic hybridization (array CGH) was used to 
study the complete genomes of type I GCTs for copy number changes. Due to the 
relative high resolution of this technique, it allowed the direct identification of 
genomic regions (1) relevant for diagnosis and/or prognosis of type I GCTs and (2) 
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containing candidate genes relevant for type I GCT development (chapter 6). In 
addition, array CGH was used in conjunction with chromosome flow-sorting for the 
direct mapping of chromosomal breakpoints (chapter 5). In chapter 7 the 
implications of these studies for our understanding of type I GCT development are 
discussed and future prospects are provided. 
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ABSTRACT 
 
Cytogenetic analysis of peripheral lymphocytes of an infantile patient with a sacral 
teratoma revealed a constitutional translocation (12;15) (q13;q25) pat. The same 
translocation was found in four additional relatives. Loss of heterozygosity analysis 
of the patients' tumor material showed retention of both translocation-derived 
chromosomes. Since allelic loss in the 12q13 region has been observed in germ cell 
tumors, we hypothesize that disregulation of gene(s) located at or near the 12q13 
breakpoint may be related to the development of this sacral teratoma. As a first step 
towards the identification of this gene(s), a 12q13 genomic contig that spans the 
breakpoint has been constructed. 
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INTRODUCTION 
 
Germ cell tumors (GCTs) form a heterogeneous group of neoplasms that occur in the 
testis and the ovary and at extragonadal sites. All these neoplasms are believed to 
evolve from pluripotent progenitor cells. Gonadal germ cell tumors are generally 
thought to originate from cells belonging to the germ cell lineage [1;2]. However, for 
extragonadal tumors the origin is still not clear. These latter tumors may develop 
from germ cells that have migrated incorrectly during embryonic development or, 
alternatively, may arise from undifferentiated pluripotent embryonic stem cells that 
have escaped the influence of developmental organizers [3-5].  
A classification of GCTs has been postulated, which was based on histology, 
anatomical localization, sex, and age of onset [6;7]. Based on this classification, the 
following four groups may be distinguished: (1) (immature) teratomas and yolk sac 
tumors of neonates and infants, (2) GCTs of the adult testicular type, (3) dermoid 
cysts (mature cystic teratomas) of the ovary and (4) spermatocytic seminomas in 
elderly men. Neoplasms of the first group are rare and are most often observed in 
female neonates in the sacral region. To a lesser extent, they appear at other 
extragonadal sites, in the ovary and in the testis. The most common site of occurrence 
of the second group is the testis of adolescent and young adult men. The dermoid 
cyst, the most frequent ovarian GCT, can be found in all age groups, but the median 
age is 30 years [8]. GCTs of the fourth group are rare and may only be found in the 
descended testis of elderly men [9]. 
Cytogenetic and molecular studies on GCTs have revealed several recurrent 
abnormalities that affect chromosome 12. As a hallmark of testicular GCTs (TGCT), 
an isochromosome of the short arm of 12, i(12p) has been identified [10;11;6]. This 
i(12p) chromosome is present in >80% of TGCTs, somewhat more frequent in non-
seminomas than in seminomas [12]. This anomaly has also been found in several 
cases of extragonadal and ovarian GCTs [13-15]. For the regions 12q13 and 12q22, 
frequent loss of heterozygosity (>40%) was observed in all histological subtypes of 
male germ cell cancer [16]. In another study, frequent (44%) deletion of 12q13-q22 
was found in non-seminomatous male GCTs and mixed male GCTs [13]. These 
findings were not confirmed by others, therefore, it is still debatable whether the 
12q13 and 12q22 regions contain tumor suppressor gene(s).  
So far, several candidate genes have been postulated that may play a role in 
the initiation or progression of TGCTs, e.g., KRAS2, JAW1 and SOX5 on 12p [17]. The 
upregulated gene(s) present on i(12p) will probably not play a role in initiation, but 
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rather in progression as suggested by Geurts van Kessel et al. [18] and, more 
recently, by Rosenberg et al. [19]. Through linkage analysis in a subgroup of familial 
TGCT cases, another locus has been suggested in the Xq27 region [20]. However, 
until now, no gene has unambiguously been identified to be involved, either in 
TGCT development or in any other form of germ cell cancer.  
The patient described in this report had an immature teratoma in the sacral 
region with a spread endodermal sinus tumor component. In addition, this patient 
had a constitutional chromosome translocation, t(12;15)(q13;q25) pat. Interestingly, 
the 12q13 breakpoint coincides with the region of allelic loss in male GCTs. In this 
study, we present the clinical data of the patient and the preliminary mapping of the 
12q13 breakpoint within a genomic contig. 
 
 
 
Figure 1. Lymphocyte-derived karyotype of the patient showing: 46,XX, t(12;15)(q13;q25). 
 
 
MATERIAL AND METHODS 
 
Karyotyping 
Peripheral blood lymphocytes were cultured in RPMI 1640 supplemented with 10% 
fetal calf serum and antibiotics for three days. Subsequently, the cells were harvested 
and metaphase spreads were prepared using standard procedures. Cytogenetic 
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analysis was carried out on trypsin-Giemsa stained slides and the karyotypes were 
described according to the International System for Human Cytogenetic 
Nomenclature [21]. 
 
A
CB
 
Figure 2. A) Section of the teratoma part of the tumor before microdissection, and B) after 
microdissection. C) Picture of the selected tumor sample used for DNA extraction. 
 
Loss of heterozygosity analysis 
For loss of heterozygosity analysis, regions containing teratoma and normal tissue 
were selected from frozen tumor samples after microscopy. From these regions, 
tissue sections of 20 micron were used for microdissection of normal cells and tumor 
cells with a laser-capture system (Arcturus Pixcell II system) (Fig. 2). Directly after 
microdissection, the tissue samples were dissolved in TNE (10mM Tris, 400 mM 
NaCl, 2 mM EDTA pH 8.2), after which proteïnase K (10 mg/ml) and SDS (10%) was 
added. After an overnight incubation at 37°C, DNA was extracted with 
phenol/chloroform/ isoamylalcohol (25:24:1) (Merck) and precipitated with 
glycogen (10 mg/ml) (Boehringer). Pellets were dissolved in TE (Tris 10mM, EDTA 
0.1 mM, pH 8.0). About 40 ng of the isolated DNA was used for PCR analysis in a 
total volume of 20 µl, containing: 2 µl of 10x PCR buffer without Mg (GIBCOBRL), 1.5 
mM MgCl2 (GIBCOBRL), 0.25 mM dNTPs (GIBCOBRL), 0.1 µl fluorescent-labeled 
dUTP R110 (PE biosystems), 50 ng of each primer, 0.08 µl Taq polymerase (5 U/µl, 
GIBCOBRL). Primers specific for the following markers were used: VWF, D12S62 
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(Genome Database accession number (GDB): 191682), D12S84 (GDB: 188005), 
GABRB3 (GDB: 188666). Samples were amplified for 30 cycles in a Perkin Elmer 2400 
GeneAmp PCR System. Each cycle included: 0.15 seconds at 94°C, 0.15 seconds at 
56°C (VWF, D12S62) or 60°C (D12S84, GABRB3) and 1 minute at 72°C. In the first 
cycle an extra denaturation step (94°C) was included for 1 minute. The fluorescent-
labeled PCR products were purified using the Qiaquick PCR purification kit 
(Qiagen). After purification they were run on 6% polyacrylamide gels (Sequagel-6, 
National Diagnostics), using an ABI 373A (Applied biosystems, Perkin Elmer), and 
analysed with the GENESCAN ANALYSIS software package (Applied Biosystems, 
Perkin Elmer). 
 
FISH analysis  
FISH analysis was carried out basically as described before [14]. on metaphase 
spreads of lymphocytes from the patient. The YAC clones (CEPH YAC library, GTC 
Leiden) used for FISH analysis were selected corresponding to markers from the 
Whitehead Contig WC12.1. These YAC clones were labeled with digoxigenin-11-
dUTP using a nick-translation kit (Boehringer Mannheim). The labeled YACs were 
coprecipitated with excess of Cot-1 DNA and, prior to hybridization, preannealed at 
37°C for 30 minutes. The slides with metaphase spread chromosomes were pre-
treated with acetic acid according to standard procedures. This was followed by 
denaturation in 70% formamide, 2 x SSC, at 70°C for 2 minutes. Hybridizations were 
carried out at 37°C over 2-3 nights. For the YACs the following fluorochrome 
conjugates and antibodies were used: sheep-anti-digoxigenin-FITC (Boehringer 
Mannheim), donkey-anti-sheep-FITC (Jackson Immuno Research Laboratories), 
rabbit-anti-FITC (Dakopatts), mouse-anti-rabbit-FITC (Jackson Immuno Research 
Laboratories). Images were captured using a Zeiss epifluorescence microscope and a 
cooled CCD camera (Photometrics) and processed using the BDS-image software 
program (Biological Detection Systems). 
 
 
RESULTS AND DISCUSSION 
 
Clinical features of the patient 
At the age of six months, the patient, a female infant, had developed a swelling near 
the sacrum and a displacement of the anus. Macroscopic examination of the swelling 
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revealed the presence of a tumor. The tumor tissue was excised and, after 
pathological examination, classified as an immature teratoma (third grade) with a 
spread endodermal sinus tumor component. Further pathological data indicated that 
the tumor was not fully removed and despite additional chemotherapy the patient 
died. Additionally, the patient exhibited some dysmorphic features, i.e., obesitas and 
an upward slant. 
 
Karyotyping of patient and relatives 
Peripheral blood lymphocytes were used for the preparation of metaphase spreads 
and karyotyping. This analysis revealed a diploid karyotype with a balanced 
translocation between the chromosomes 12 and 15, t(12;15)(q13;q25) (Fig. 1). To 
determine whether this translocation had occurred de novo, the parents were also 
karyotyped. The father appeared to be a carrier of the same translocation. Based on 
this observation, additional family members were examined cytogenetically. The 
grandfather, a paternal uncle and a sister of the patient also turned out to have the 
same t(12;15)(q13;q25). The patients’dysmorphic features were not seen in any of 
these translocation carriers nor did any of them develop a germ cell tumor. 
 
Figure 3. Allele plots derived from tumor and normal tissue of the patient using four markers: 
A) D12S84, B) VWF, C) D12S62, D) GABRB3. Sizes of the alleles are indicated below the plots. 
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LOH analysis of tumor tissue 
Given the fact that loss of translocation derivative chromosomes in renal cell tumors 
from patients with constitutional translocations has frequently been observed [22;23], 
we initiated a loss of heterozygosity (LOH) study on the tumor material of this 
patient. Therefore, tissue from the teratoma part of the tumor and normal tissue 
surrounding the tumor were microdissected (Fig. 2). DNA was extracted from these 
tissues and used for LOH analysis with known genetic markers. The markers VWF 
and D12S62 map on chromosome 12 above the breakpoint and, thus, are informative 
for the presence of der(12). D12S84, which maps distal to the breakpoint on 
chromosome 12, and GABRB3, a marker proximal to the breakpoint on chromosome 
15, are informative for the presence of der(15). As shown in figure 3, similar allele 
patterns were observed for all four markers in both tumor and normal tissues. This 
result indicates that the tumor tissue of this patient is heterozygous for all four 
markers tested and thus both the der(12) and der(15) have been retained in the tumor 
cells. From these results we conclude that loss of either one of the translocation 
chromosomes is not associated with the development of this sacral teratoma. 
 
 
Figure 4. A) Diagram showing: chromosome 12, a series of q13.1 markers and the corresponding 
CEPH YACs. B) FISH analysis with YAC 919-G-8 on a lymphocyte derived metaphase spread from the 
patient. Positive signals (green) on both der(12) and der(15) and on the normal chromosome 12 are 
indicated. Chromosomes are shown in red. 
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Mapping of the 12q13 breakpoint within a YAC contig 
Since the translocation breakpoint itself might be relevant for the development of the 
sacral teratoma, we initiated the physical mapping of the 12q13 breakpoint. Several 
YACs were selected within this region and used as probes for FISH analysis on 
metaphase spreads of peripheral blood lymphocytes from the patient. Figure 4A 
shows the selected YACs and their corresponding genetic markers. YAC 893-A-3, 
881-D-8, 944-A-5 and 754-A-1 all displayed FISH signals on chromosome 12 and 
der(12), indicating that these YACs map centromeric to the breakpoint on 
chromosome 12. YAC 796-H-12 gave signals telomeric to the breakpoint on 
chromosome 12 and on der(15). In contrast, YAC 919-G-8 gave, besides on 
chromosome 12, signals on both der(12) and der(15), indicating that this YAC spans 
the 12q13 breakpoint (Fig. 4B). This YAC may serve as a starting point to identify the 
gene(s) involved. 
In order to explain the occurrence of dysmorphic features and a sacral 
teratoma in the patient, and lack of these anomalies in the other translocation-
positive relatives including the father, one could speculate that additional 
submicroscopic changes (duplications or deletions) may be present in one of the 
translocation derivatives of the patient, leading to abnormal gene regulation and/or 
expression. These changes could have taken place due to an aberrant pairing and/or 
segregation of the translocation chromosomes during the first meiotic division of the 
primary spermatocytes, a phenomenon that has been observed in other translocation 
cases [24]. Another possibility is that the 12q13 allele on the normal chromosome 12 
is mutated somatically and contributes to tumorigenesis through a classical two-hit 
scenario [25;26]. Currently we are investigating what gene(s) is involved in the 
translocation and whether this gene(s) is differently affected in the patient as 
compared to the other translocation carriers. 
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ABSTRACT 
 
Recently we identified a patient with an infantile sacrococcygeal teratoma and a 
constitutional t(12;15)(q13;q25). Here we show that, as a result of this chromosomal 
translocation, the SUMO/Sentrin-specific protease 1 gene (SENP1) on chromosome 
12 and the embryonic polarity-related mesoderm development gene (MESDC2) on 
chromosome 15 are disrupted and fused. Both reciprocal SENP1-MESDC2 (SEME) 
and MESDC2-SENP1 (MESE) fusion genes are transcribed in tumor-derived cells and 
their open reading frames encode aberrant proteins. As a consequence of this, and in 
contrast to wild-type (WT) MESDC2, the translocation associated SEME protein is no 
longer targeted to the endoplasmatic reticulum, leading to a presumed loss of 
function as a chaperone for the WNT co-receptors LRP5 and/or LRP6. Ultimately, 
this might lead to abnormal development and/or routing of germ cell tumor 
precursor cells. SUMO, a post-translational modifier plays an important role in 
several cellular key processes and is cleaved from its substrates by WT SENP1. Using 
a PML desumoylation assay we found that translocation-associated MESE proteins 
exhibit desumoylation capacities similar to those observed for WT SENP1. We 
speculate that spatio-temporal disturbances in desumoylating activities during 
critical stages of embryonic development might have predisposed the patient. 
Together, the constitutional t(12;15)(q13;q25) translocation revealed two novel 
candidate genes for neonatal/infantile GCT development: MESDC2 and SENP1. 
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INTRODUCTION  
 
Human germ cell tumors (GCTs) can arise at various ages, in both sexes, at different 
body locations and vary with respect to clinical outcome, histology and genetic 
constitution [1-3]. GCTs are most prevalent in the testis of young adult males. We 
and others have suggested that GCTs of infants and neonates may represent a 
distinct subgroup [2-8]. These latter tumors are relatively rare, mainly arise in the 
sacral/sacrococcygeal region and, at a lower frequency, in the gonads and along the 
midline of the body [3]. How these tumors develop and from which precursor cells 
they originate is still a matter of debate. A common precursor cell type, however, has 
been suggested for infantile gonadal and extra-gonadal GCTs [9]. The main 
histological infantile subtypes include teratomas with mesodermal, ectodermal and 
endodermal components, and yolk sac tumors with yolk sac endodermal 
components. Teratoma development resembles embryogenesis in various aspects 
[10;11]. Therefore, these latter tumors have been used as model systems to study both 
early embryonic and tumorigenic processes [12;13]. 
Currently available information on the cytogenetic constitution of neonatal 
and infantile GCTs indicates that teratomas are mostly diploid with only minor non-
recurrent chromosomal anomalies. In contrast, infantile yolk sac tumors exhibit 
several major recurrent chromosomal aberrations [7;8;15-18]. Overall, the most 
frequent cytogenetic anomaly in GCTs is the i(12p) chromosome. This marker 
chromosome is almost exclusively present in testicular GCTs of juveniles and adults 
[19]. Several recurrent genomic anomalies in both neonatal/infantile and 
juvenile/adult GCTs are currently under investigation [20-24]. So far, however, no 
gene that is causally related to GCT development has unambiguously been 
identified, not for the infantile type nor for the adult type.  
Using linkage analysis, Rapley et al. [25] identified a locus on Xq27 for familial 
testicular germ cell cancer. Additional candidate regions harboring putative genes 
for familial GCT development include 16p13, 18q22-qter and 12q12-13 [26]. Together 
with the 12q22 region, the 12q12-13 region was found to be frequently deleted in 
sporadic GCTs as well [27-29]. Linkage and CGH studies typically result in the 
identification of relatively large tumor-related genomic intervals containing 
numerous candidate genes. Recurrent, apparently balanced chromosomal anomalies, 
however, provide an opportunity to overcome this problem. Constitutional 
chromosome translocations have been widely employed to identify candidate genes 
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in various (hereditary) cancer syndromes [30-33]. Recently, we detected a patient 
with an infantile sacrococcygeal teratoma and a constitutional t(12;15)(q13;q25) [34]. 
Here we show that this translocation results in a fusion of the SUMO/Sentrin-
specific protease 1 gene SENP1 on 12q13 and the embryonic polarity-related 
mesoderm development gene MESDC2 on 15q25. The putative implications of this 
novel gene fusion in the context of GCT development are discussed. 
 
 
RESULTS 
 
Figure 1. Mapping of the 12q13 breakpoint within the SENP1 gene. A) Diagram depicting 
chromosome 12, the breakpoint-spanning CEPH YAC clone 919G8, its corresponding PAC contig and 
the genes corresponding to the breakpoint-spanning PAC clone RP1-228p16. The breakpoint 
spanning clones and gene are depicted in gray. B) Southern blot analysis of the t(12;15)(q13;q25)-
positive cell line (lane 1) and its derived somatic cell hybrids (lane 2: chromosome 12; lane 3: 
der(15); lane 4: der(12)) after digestion of the DNAs with HindIII or BglII. A PCR fragment obtained 
with primer pair 228p16-38 and located proximal to the breakpoint was used as a probe. Next to the 
WT chromosome 12 fragments (lanes 1 and 2: 4.1kb HindIII fragment and 6.7 kb BglII fragment) 
shifted fragments are readily seen in the original cell line (lane 1) and the der(15)-containing hybrid 
(lane 3: >12kb HindIII and ~11kb BglII fragments, respectively). A cross-hybridizing Chinese hamster 
fragment is marked by an arrowhead. 
 
SENP1 is disrupted by the 12q13 breakpoint 
Previously, we identified a YAC clone (CEPH-919G8) that spans the constitutional 
t(12;15)(q13;q25) breakpoint at 12q13 [5]. In order to refine this breakpoint region, a 
PAC contig was assembled that corresponds to this YAC clone (Fig. 1A). FISH 
analysis on metaphase spreads of t(12;15)(q13;q25)-positive cells revealed that PAC 
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clones RP1-316M24, RP1-130F5 and RP3-197B17 map proximal to the breakpoint and 
that, in contrast, RP1-228P16 turned out to be a breakpoint spanning clone. This 
finding is in full concordance with our subsequent array CGH-based mapping data 
[35]. The complete sequence of RP1-228P16 is available in GenBank (accession no. 
AC004801) and, according to the May 2004 human genome assembly freeze 
(http://genome.ucsc.edu/), it encompasses four positional candidate genes: 
MGC5576 (a hypothetical gene), COL2A1, SENP1 and PFKM (Fig. 1A).  
To facilitate further refinement of the chromosomal breakpoint position in 
RP1-228P16 the t(12;15)(q13;q25)-associated chromosomes were segregated by 
generating Chinese hamster-human somatic cell hybrids. These hybrid cell lines with 
either the normal chromosome 12, the derivative chromosome 12 (der(12)) or the 
derivative chromosome 15 (der(15)) were employed for STS-content mapping using 
specific PCR primer sets from pre-selected regions within RP1-228P16. The original 
t(12;15)(q13;q25)-positive lymphoblastoid cell line was included as a positive control. 
By doing so, the breakpoint interval could be reduced to a 3.6 kb genomic interval 
(data not shown).  
In order to confirm these PCR results and to further narrow down the 
breakpoint region, Southern blot analysis was performed using HindIII and BglII 
digested DNAs extracted from the original and hybrid cell lines. A PCR fragment 
generated by one of the breakpoint-flanking primer sets (228p16-38) was used as 
probe. As expected, this probe hybridized to both HindIII and BglII wild-type (WT) 
fragments of respectively 4.1 and 6.7 kb in the t(12;15)(q13;q25)-positive cell line and 
the chromosome 12-positive hybrid cell line (Fig. 1B, lanes 1 and 2). In addition, 
aberrantly hybridizing fragments were observed in the HindIII (>12kb) and BglII (~10 
kb) digested DNAs of the t(12;15)(q13;q25)-positive cell line and the der(15)-positive 
hybrid cell line (lanes 1 and 3, respectively). These shifted fragments were absent in 
the der(12)-positive hybrid cell line (lane 4), indicating that they originate from the 
der(15). Together, the PCR and Southern blot results reduced the 12q13 breakpoint 
region to a 2.4 kb genomic interval. Analysis of its sequence using the UCSC human 
genome browser (May 2004 freeze) revealed that it is located within the second 
intron of one of the four earlier mentioned candidate genes: SENP1 (Fig. 2A). SENP1 
belongs to the family of SUMO/Sentrin-specific proteases which are known to be 
involved in the cleavage of SUMO proteins from their substrates [36]. The SENP1 
gene is ~63 kb in size and encodes an mRNA of 4.7 kb (GenBank accession no. 
NM_014554). The May 2004 freeze of the UCSC human genome browser reveals 
several different mRNA splice variants that differ in their first exons, the length of 
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their 3’-UTRs and/or the number of (additional) exons. The largest open reading 
frame (ORF) encodes a 643 amino acids protein that corresponds to the WT protein 
described by Gong et al. [36]. 
 
Figure 2. Fusion of SENP1 on chromosome 12 and MESDC2 on chromosome 15. A) Diagram 
showing SENP1 and MESDC2 and the respective positions of the breakpoints in introns 2 and 1. B) 
3’RACE products obtained from normal control and t(12;15)(q13;q25)-positive lymphoblastoid cell 
lines, and sequences of t(12;15)(q13;q25)-derived SENP1-MESDC2 fusion products. C) RT-PCR 
analysis of SENP1-MESDC2 (SEME), MESDC2-SENP1 (MESE), SENP1 and MESDC2 in the tumor sample, a 
positive control cell line (either the original t(12;15)(q13;q25)-positive lymphoblastoid cell line or, 
for MESDC2, a lymphoblastoid cell line from a healthy individual), and a negative control. D) PCR 
analysis of the fusion genes SENP1-MESDC2 (SEME) on der(15) and MESDC2-SENP1 (MESE) on der(12) 
in the paternal t(12;15)(q13;q25)-positive lymphoblastoid cell line, the patient-derived tumor 
sample, and a negative control. 
 
SENP1 is fused to MESDC2 at 15q25 
On the basis of the localization of the 12q13 breakpoint within SENP1, we set out to 
identify the breakpoint sequences present at 15q25. To this end 3’-rapid amplification 
of cDNA ends (3’RACE) analysis was performed using the SENP1 breakpoint 
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information as a starting point. cDNAs generated from the t(12;15)(q13;q25)-positive 
lymphoblastoid cell line and, as a control, cDNAs from an unrelated lymphoblastoid 
cell line without a t(12;15)(q13;q25) were used. Aberrant PCR-fragments only present 
in the t(12;15)(q13;q25)-positive cell line were cloned, sequenced and analyzed (Fig. 
2B). This resulted in the identification of chimeric transcripts, consisting of SENP1 
sequences fused to sequences from MESDC2, a gene located at the 15q25 breakpoint 
region. More specifically, the MESDC2 gene is located in BAC clone RP11-775C24, 
again completely in line with our array CGH-based mapping data [35]. The 
breakpoint in the MESDC2 gene appeared to be located within its first intron (Fig. 
2A). MESDC2 (mesoderm development gene) is an embryonic polarity related gene 
[37;38] of about 14 kb in size and encodes a 4.2 kb mRNA corresponding to a 
deduced protein of 234 amino acids (GenBank accession no. D42039). Also, for this 
gene additional mRNAs that differ in length at their ‘3-UTR are reported in the May 
2004 freeze of the UCSC human genome browser. 
 The presence of SENP1-MESDC2 fusion transcripts (here referred to as SEME) 
in the t(12;15)(q13;q25)-positive cell line was confirmed by reverse transcription-
polymerase chain reaction (RT-PCR). Similarly, the presence of SEME was confirmed 
in the primary tumor sample of the patient as well (Fig. 2C, first panel). Additionally, 
RT-PCR showed the presence of the reciprocal MESDC2-SENP1 transcript (referred 
to as MESE) and the WT SENP1 and MESDC2 transcripts in the primary tumor 
sample (Fig. 2C). 
 The t(12;15)(q13;q25)-positive lymphoblastoid cell line that we used for 
mapping of the breakpoints was derived from the patient’s father. In order to verify 
whether the genomic breakpoints identified in this cell line are in conformity to those 
in the patient, we performed PCR analysis on genomic DNAs extracted from the 
tumor material of the patient and the t(12;15)(q13;q25)-positive cell line. In both cases 
similar PCR products were obtained (Fig. 2D) and their sequences revealed that both 
breakpoints were identical at the base-pair level, thereby ruling out breakpoint-
flanking duplications and/or deletions in the patient due to incomplete pairing and 
unequal crossing over of the respective derivative chromosomes at the breakpoints 
during meiotic division. In addition, we sequenced the complete ORFs of SENP1 and 
MESDC2 from the tumor-derived DNA and no additional (somatic) mutations were 
detected. 
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MESE has retained desumoylating activity 
The reciprocal MESE fusion transcript is composed of the first exon of MESDC2 
followed by exons 3-18 of SENP1. Owing to the translocation, the original start codon 
of SENP1 [36] is lost and two alternative ORFs are predicted for this MESE transcript. 
Depending on which ATG is used as a start codon, the encoded protein represents 
either an aberrant MESDC2 protein with 71 in frame N-terminal amino acids 
followed by six additional amino acids or a protein that is almost completely 
composed of SENP1 except for the second amino acid at the N-terminus (here 
referred to as MESE 1.2). Using RT-PCR, we detected an additional MESE transcript 
containing an aberrant exon 1 of MESDC2 (lacking 199 bp at the 3’-end) and exons 3-
18 of SENP1 in the t(12;15)(q13;q25)-positive lymphoblastoid cell line. The predicted 
ORF of this transcript encodes a putative protein that lacks 8 amino acids at the N-
terminus as compared with WT SENP1 (here referred to as MESE 11.4). The two 
aberrant SENP1 proteins (MESE 1.2 and 11.4) encoded by the largest predicted ORFs 
contain the known SENP1 functional domains, i.e., the nuclear localization signal 
NLS and the protease domain (Fig. 3) [36;39].  
Figure 3. Diagram showing the proteins encoded by WT SENP1 and MESDC2 genes and the SEME 
and MESE fusion genes. Functional domains and the respective breakpoints are marked.  
 
SENP1 is a SUMO/Sentrin-specific protease that can cleave SUMO-1 from 
target proteins such as PML [36;40]. To examine whether the MESE proteins have 
retained this functional capacity, we performed desumoylation assays using PML as 
a target. Therefore, COS-1 cells were transfected with one or more of the following 
expression constructs: His-PML, Ha-SUMO-1, MESE-VSV (1.2 or 11.4), WT SENP1-
VSV and/or a control empty vector (Fig. 4). His-PML proteins with or without a 
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conjugated Ha-SUMO-1 protein were purified from the cell lysates by 
immunoprecipitation (IP) using an anti-polyhistidine antibody. Multiple SUMO-1 
associated PML isoforms were readily detected in the lysates of COS-1 cells 
expressing SUMO-1 and PML (Fig. 4; sumoylated PML, upper panel, lane 3). These 
isoforms were not detected in control IP samples of COS-1 cells transfected with 
empty vectors in conjunction with vectors without (lane 1) or with (lane 2) PML. 
Also, COS-1 cells expressing WT SENP1 together with SUMO-1 and PML did not 
show any sumoylated isoforms of PML (lane 4), indicating that the majority of PML 
protein is indeed desumoylated by SENP1. Similarly, IPs of COS-1 cells expressing 
MESE (11.4 or 1.2) together with PML and SUMO-1 (lane 5 and 6) did not show any 
sumoylated isoforms of PML, indicating that, although both MESE proteins were 
expressed at a lower level than WT SENP1 (Fig. 4; SENP1 variants), they still were 
fully capable of desumoylating PML. 
Figure 4. PML desumoylation assay with VSV-tagged SENP1 and MESE (1.2 and 11.4) proteins. 
COS-1 cells were transfected with one or more of the following constructs: His-PML, Ha-SUMO-1, WT 
SENP1-VSV, MESE-VSV (11.4), MESE-VSV (1.2), or empty vector (PSG8). His-PML proteins were pulled 
down with the anti-polyhistidine antibody using IP (anti-polyhistidine IP) and subsequently detected 
on western blots: sumoylated His-PML with the anti-Ha antibody and desumoylated His-PML with the 
anti-polyhistidine antibody. SENP1 variants were visualized in the total cell lysates using an anti-VSV 
antibody. The molecular weights (in kilodaltons) from co-electrophoresed markers are indicated. 
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Anomalous subcellular localization of SEME 
WT MESDC2 contains a putative N-terminal signal sequence and a non-conserved C-
terminal ER-retention signal (Fig. 3). Previously, it was shown that a flag-tagged 
mouse homologue of MESDC2 co-localizes with the luminal ER protein calreticulin 
in COS-1 cells [38]. In this study, we independently confirmed this localization by 
showing that a VSV-tagged human MESDC2 co-localizes with the ER protein PDI in 
HeLa cells (Fig. 5A). The translocation-related SEME fusion transcript contains the 
first two exons of SENP1 and exon 2 and 3 of MESDC2. A predicted ORF encodes a 
MESDC2 protein that lacks 106 amino acids at the N-terminus when compared with 
WT MESDC2 (Fig. 3). In addition, we detected a splice variant of SEME without the 
SENP1 exon 2 in de tumor material (SEME-2). The predicted ORF of this splice 
variant lacks 71 N-terminal MESDC2 amino acids and, instead, contains 7 additional 
amino acids. Owing to the truncations, both SEME proteins lack the putative signal 
peptide that is required for transport to the ER. Indeed, exogeneous expression of 
VSV-tagged SEME in HeLa cells revealed a diffuse staining pattern throughout the 
cytoplasm and no co-localization with PDI was observed (Fig. 5B). Therefore, we 
conclude that SEME is not localized at or in the ER. Control empty vector cells failed 
to yield any signals using the anti-VSV and secondary antibodies (not shown). 
 
 
Figure 5. Subcellular localization of A) MESDC2 and B) SEME, using C-terminal VSV tags and SV40 
promoters, after transient expression in HeLa cells. The proteins were visualized using an anti-VSV 
antibody (green; left panels). Endogenous PDI, an ER resident protein, was visualized with an anti-
PDI antibody (red; middle panels). Overlays are shown in the right panels. 
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DISCUSSION 
 
Recently, we presented a novel case of a sacrococcygeal teratoma from an infantile 
patient carrying a constitutional t(12;15)(q13;q25). LOH experiments confirmed the 
presence of both reciprocal derivative chromosomes in the tumor material [34]. In 
addition to this constitutional translocation, we identified one additional (somatic) 
cytogenetic aberration in this tumor, i.e., amplification of 20q and deletion of 20p 
[18]. Since the 12q13 region is recurrently affected in human germ cell tumors [27;28], 
we set out to characterize this constitutional t(12;15)(q13;q25) translocation in detail. 
Using positional cloning strategies, we found that the breakpoints on chromosome 12 
and chromosome 15 disrupt two genes, i.e., SENP1 and MESDC2, respectively. This 
resulted in the formation of two reciprocal fusion genes: SENP1-MESDC2 on the 
der(15) and MESDC2-SENP1 on the der(12). Next to the respective WT genes, both 
fusion genes (here referred to as SEME and MESE) appeared to be transcribed in the 
tumor tissue, and functional ORFs were predicted from them.  
 SUMO/Sentrin is an ubiquitin-like protein that covalently attaches to lysine 
residues in substrate proteins as a post-translational modification. In vertebrates 
three SUMO family members have been described, i.e., SUMO-1, -2 and -3 [41;42]. In 
contrast to ubiquitin, SUMO does not target proteins for proteasomal destruction. 
Instead, SUMO modification appears to be involved in the regulation of various 
cellular key processes, including transcriptional regulation, nuclear transport, 
maintenance of genome integrity, and signal transduction [43-45]. The SENP1 gene 
was first identified by Gong et al. [36] and encodes a cysteine-specific protease that 
deconjugates SUMO-1 from its target proteins. A recent in vitro study showed that 
SENP1 can also preprocess SUMO-1, -2 and -3 from their precursor forms [46]. So far, 
seven SUMO-related proteases have been identified and deposited in the Genbank 
database (SENP1-SENP7). These proteases are homologous at their C-termini, a 
region that contains a conserved protease domain, the HIS/ASP/CYS catalytic triad. 
On the basis of the differences in subcellular localization and mRNA expression 
patterns, substrate specificities have been suggested for the various SENP family 
members [39;47-50]. Interestingly, one of the family members, SENP6 (SUSP1) was 
recently found to be disrupted and fused to the TCBA1 gene in the lymphoma-
derived cell line HT-1 [51]. Also, SENP1 was detected as one of the 30 overexpressed 
genes in thyroid oncocytic tumors, using a two-step differential RT-PCR assay [52]. 
Together with the present study these findings strengthen a possible role for this 
protease family in cancer development. 
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Through a PML desumoylation assay we established that the two 
translocation-associated MESE proteins (differing in only eight or one amino acid(s) 
from WT SENP1, respectively) exhibited desumoylation capacities similar to that 
observed for WT SENP1. In addition, the MESDC2-SENP1 fusion gene is under the 
control of the MESDC2 promoter. Therefore, we speculate that spatio-temporal 
disturbances in desumoylating activities during critical stages of embryonic 
development may lead to an abnormal regulation of gene transcription, nuclear 
transport, genome integrity and/or signal transduction in GCT precursor cells. In 
addition to these promoter-swap related phenomena, it should be noted that N-
terminal truncation of the SENP1 protein may have additional in vivo effects on its 
biological activity and/or its substrate specificity. Such disturbances may have 
predisposed our patient to GCT development. 
The mouse homologue of MESDC2 (aliases: Mesd in mouse, KIAA0081 in 
human, BOCA in fly) was first identified as a candidate gene present in the mouse 
proximal albino deletion interval that is critical for mesoderm differentiation and 
polarity during embryonic development [37]. Embryos homozygous for this deletion 
are lethal, fail to develop mesodermal structures and do not form a primitive streak 
[53]. Hsieh et al. [38] demonstrated by transgene rescue that Mesd is the gene that is 
responsible for the polarity defects and embryonic lethality in these mice. 
Subsequently, transient expression in COS-1 cells demonstrated that Mesd may act as 
a chaperone located in the ER that facilitates the membrane localization and prevents 
the aggregation of LDL receptor family members like the WNT co-receptors LRP5 
and LRP6 [38;54]. In this study we show that, in contrast to WT MESDC2, the 
translocation-associated SEME protein is no longer restricted to the ER. 
Consequently, it may have lost its capacity to act as a chaperone for the LDL 
receptors LRP5 and/or LRP6. Like the MESDC2-SENP1 fusion gene, the SENP1-
MESDC2 fusion gene also has undergone a promoter-swap. Again, such a swap may 
have spatio-temporal consequences during early embryogenesis, including an 
abnormal development and/or routing of GCT precursor cells. Obviously, additional 
studies are required to establish a definite role for desumoylation, LDL receptor 
aggregation or both, on the (de)regulation of GCT precursor cells. This novel 
constitutional chromosome translocation, however, appears to have revealed novel 
leads to candidate genes and pathways critical to the development of 
neonatal/infantile GCTs. 
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MATERIALS AND METHODS 
 
Patient material and somatic cell hybrids 
Peripheral blood lymphocytes were used (informed consent) to generate an immortal 
t(12;15)(q13;q25)-positive cell line after in vitro Epstein-Barr virus (EBV) 
transformation using standard procedures. For the preparation of somatic cell 
hybrids, these t(12;15)(q13;q25)-positive cells were fused with thymidine kinase–
deficient Chinese hamster A3 cells as described before [55]. Subsequently, 
independent somatic cell hybrids were isolated after hypoxanthine-aminoterine-
thymidine (HAT) selection and their human chromosomal constitution was 
established through karyotyping, FISH analysis and PCR-screening with primers: 
D12S63, D12S85, D12S1661 and D12S1701. Hybrid cell lines that contained the 
normal chromosome 12, the der(15) or the der(12), respectively, were selected for 
further analysis. No other chromosome 12 or chromosome 15 material was detected 
in these selected hybrid cell lines. 
 
FISH analysis 
Metaphase spreads from the t(12;15)(q13;q25)-positive cell line and its derived 
somatic cell hybrids were used for FISH analysis. Probe labeling, slide preparation, 
and hybridization were performed essentially as described before [34;56]. The 
following clones were used for FISH analysis: RP1-316M24, RP1-130F5, RP3-197B17, 
RP1-228P16 (BACPAC Resources, Oakland, USA). A Zeiss epifluorescence 
microscope equipped with appropriate filters was used for visual examination of the 
slides. Digital images were captured using a high-performance cooled CCD camera 
(Photometrics) coupled to a Macintosh Quadra 950 computer and processed using 
the Oncor-image software (Gaithersburgh, MD, USA). 
 
PCR and Southern blot analysis 
Genomic DNAs were isolated as described previously [57]. For mapping of the 12q13 
breakpoint, genomic DNAs of the parental and hybrid cell lines were analyzed using 
different primer sets including those flanking the breakpoint, i.e.: 
228p16-38:   228p16-38F; TCACTTCTAGTGGCTGCACC 
228p16-38R; AAACCCATTCTTTCACTACAGC 
228p16-41:  228p16-41F; GAGTTCTTTGAGAACAGTACG 
228p16-41R; ATAGCACAGACATCTTAGAGC 
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The PCR fragment of primer set 228p16-38 was subsequently labeled with [α-
32P]dCTP by random priming and used as a probe on Southern blots containing 
BglII- and HindIII-digested parental and hybrid cell-derived DNAs. 
 
3’RACE and RT–PCR analyses  
Total RNA was isolated from the t(12;15)(q13;q25)-positive lymphoblastoid cell line 
and a control lymphoblastoid cell line using RNAzol B (Campro Scientific, 
Veenendaal, The Netherlands) according to the instructions of the manufacturer. RT-
PCR was performed using Superscript II (Life Technologies, Gaithersburg, MD, 
USA), 5 μg of total RNA, the oligodT primer 
(AAGGATCCGTCGACATCTTTTTTTTTTTTTTTTT) and a random hexamer-mix 
(Invitrogen, Breda, The Netherlands), again according to the instructions of the 
manufacturer. 3’RACE analysis was carried out in two PCR steps. The first PCR was 
performed with a specific forward primer located in the first exon of SENP1 
(GACTCTTCCGGTGCTGT) and a primer that hybridizes to the oligodT primer 
sequences (CUACUACUACUAAAGGATCCGTCGACATC). This PCR was carried 
out under standard conditions using 10 pmol of priming oligonucleotides. Samples 
were amplified during 30 cycles in a Perkin Elmer 2400 GeneAmp PCR System. Each 
cycle included: 1 minute at 94°C, 1 minute at 55°C and 3 minutes at 72°C. In the first 
cycle an extra denaturation step (94°C) was included for 1 minute and the last cycle 
was extended at 72°C for 5 minutes. Subsequently, the PCR sample was diluted 10 
times and used for the second PCR step, a hemi-nested PCR. Therefore, the following 
primers were used: a nested forward primer located in the first exon of SENP1 
(CATCATCATCATCTGTGAAGGCGGTTCC) and the reverse primer that hybridizes 
to the oligodT primer sequences. PCR analyzes (35 cycles) included: 30 seconds at 
94°C,  30 seconds at 55°C and 3 minutes at 72°C. In the first cycle an extra 
denaturation step (94°C) was included for 2 minutes and the last cycle was extended 
at 72°C for 5 minutes. The PCR samples were loaded onto standard agarose-gels and 
bands were sliced out, purified by standard procedures, ligated into pGEM-T vectors 
(Promega, Leiden, The Netherlands) according to the instructions of the 
manufacturer, and sequenced using SP6-and T7-specific primers. For additional PCR 
analyzes the following primers were used:  
Sprot-exon5R; GAGGTCTTTCGGGTTTCGAGG 
Sprot-exon3R; AGCGAAAGCTGGTCCTCTGG 
Sprot-raceFnest; CGCATGGCAGCCGGTTCCG 
KIAA0081-exon3R; TTGCCCTTGTCTTGCTTTG 
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KIAA0081-exon1F; TTGTGCCTCTGACCTGCTGC 
KIAA0081-exon2R; CCTTCTCAGTAGGGCTTCC. 
 
Plasmid constructs 
On the basis of the published sequences of SENP1 [36] and MESDC2 (GenBank 
accession no.: KIAA0081, BC009210) [37;38] cDNAs of SENP1, SENP1-MESDC2 
(SEME), MESDC2-SENP1 (MESE) were generated by RT-PCR on RNA extracted 
from the t(12;15)(q13;q25)-positive cell line using the oligodT primer, the random 
hexamer-mix and Sprotex1-EcoRI-F (CGGAATTCTCTTCCGGTGCTGTGAAGG), 
Sprotex18-NheI-R (CTAGCTAGCTAGGAGTTTTCGGTGGAGGATC), 5-BC009210-F  
(GGAATTCGGTAAGCGCGTCTAGGG). For the MESDC2 construct cDNA was 
derived from a clone (3637449) of the I.M.A.G.E. Consortium [58], using a primer 
specific for the SP6 promoter and 3-Mesdc2-R 
(GACTAGTGTCTTCTCTTTTATTCCCAGC). These cDNAs were cloned into a 
eukaryotic expression vector PSG8 [59] in frame with a VSV-tag at their 3’-end. His-
PML and Ha-SUMO-1 constructs were described before [36;60]. 
 
Cellular localization assays 
HeLa cells were transfected directly on glass slides using FuGENE 6 (Roche 
Diagnostics, Mannheim, Germany) according to the instructions of the manufacturer. 
Immunofluorescence assays were performed essentially as described before [61]. The 
following antibodies were used for immunostaining: the monoclonal mouse anti-
VSV antibody (1:1000) (Sigma Genosys, Cambridge, UK), the rabbit anti-PDI (1:10) 
[62], followed by appropriate FITC or Texas Red-conjugated goat-anti-mouse or goat-
anti-rabbit antibodies (1:100) (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA). Images were recorded using a Zeiss LSM510 META confocal microscope 
running software release 3.2. 
 
PML desumoylation assay 
COS-1 cells were transfected by nucleofection (Amaxa, Koeln, Germany) according to 
the instructions of the manufacturer with one or more of the following constructs 
(displayed in Fig. 4): His-PML, Ha-SUMO-1, MESE-VSV (11.4), MESE-VSV (1.2), WT 
SENP1-VSV or empty vector (PSG8). Approximately 24 hours after transfection the 
cells were washed in ice-cold PBS and lysed in ice-cold lysisbuffer (50 mM Hepes ph 
7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5% NP-40, 0.3% Triton X-100) 
supplemented with protease inhibitors (100x dilution of 0,5 M DTE, 2M 
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ethylmaleimide, complete cocktail (Roche Diagnostics, Mannheim, Germany), 100 
mM PMSF). Before IP, aliquotes of the cell lysates were used to assay the expression 
levels from the different SENP1-VSV constructs. For IP-mediated extraction of the 
PML conjugates, a monoclonal anti-polyhistidine antibody (Sigma Genosys, 
Cambridge, UK) was added to the cell lysates (100x dilution) and mixed by tumbling 
for minimal 4 hours at 4˚C. Subsequently, protein A beads (Sigma Genosys, 
Cambridge, UK) were added (10% v/v) after washing with ice-cold lysisbuffer, and 
mixed by tumbling for an additional 1-2 hours at 4˚C. After several washes, the 
samples (before and after IP) were boiled for 5 minutes in SDS sample buffer before 
loading onto SDS polyacrylamide gels (7.5%) and, subsequently, transferred to 
PROTRAN nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). For 
immunodetection of the samples on the membranes, a mouse anti-Ha (1:1000), a 
mouse monoclonal anti-polyhistidine (1:3000) and an anti-VSV (1:10) (P5D4) 
antibody were used. As secondary antibodies a rabbit anti-mouse-HRP or a swine-
anti-rabbit-HRP were used (1:1000) (DAKO, Denmark). Immunostaining was 
performed using chemoluminesence. 
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ABSTRACT 
 
Recently, we identified a patient with an infantile germ cell tumour (sacral teratoma) 
and a constitutional t(8;12)(q23;q12). Since the 12q11-q13 region is thought to harbour 
one or more genes relevant for germ cell tumour development, we set out to 
positionally clone this novel constitutional translocation. Using FISH and Southern 
blot analyses in conjunction with vectorette-PCR we were able to position the 8q23 
breakpoint ~13 kb upstream of the EIF3S6 gene and the 12q12 breakpoint ~50kb 
downstream of the DKFZP434G1415 gene. As yet, no breakpoint-spanning (fusion) 
genes could be identified. Preliminary northern blot analyses revealed that the 
transcription levels of several positional candidate genes, including EIF3S6 and 
DKFZP434G1415, were not significantly affected by the translocation. We conclude 
that additional information is required to definitely establish the role of this 
constitutional translocation and its associated genes in the development of infantile 
sacral teratomas and/or other related germ cell tumours. 
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INTRODUCTION 
 
Human germ cell tumours (GCTs) comprise a heterogeneous group of tumours that 
differ with respect to their age of onset, anatomical location, histology, chromosomal 
constitution and clinical behaviour. Based on these differences, human GCTs can be 
categorized into five different groups: (1) teratomas and yolk sac tumours (YSTs) in 
neonates and infants (2) GCTs of the adult testicular type, i.e., seminomas and non-
seminomas, (3) spermatocytic seminomas in elderly men, (4) dermoid cysts (mature 
cystic teratomas) of the ovary, and (5) hydatidiform moles of the placenta/uterus 
[1;2]. The neonatal/infantile group of GCTs is relatively rare and these tumours 
mainly arise in the sacral/sacrococcygeal region. Previous molecular cytogenetic 
studies have shown that the teratomas of this group are predominantly diploid with 
only a few non-recurrent genomic anomalies [3]. In contrast, we and others found 
that the YSTs of this group frequently exhibit aneuploidies, including recurrent 
losses of 1p and 6q, and recurrent gains of 20q [4-8]. Testicular GCTs of juveniles and 
adults are the most frequently occurring GCTs with numerical and structural 
anomalies of chromosome 12, in particular i(12p), as their genetic hallmark [9-11]. 
Recently, we detected a 6 year old patient with a sacral teratoma and a 
constitutional t(8;12)(q23;q12) translocation [12]. The 12q12 breakpoint region in this 
patient is of particular interest since several studies have implied the presence of one 
or more genes relevant for GCT development within this region. Cytogenetic 
analysis of sixty-five male GCTs revealed eight cases with a deletion of the 12q11-q22 
region and three cases with a translocation of the 12q11-q13 region [13;14]. In a 
follow-up study of forty-five male GCTs frequent losses of heterozygosity (LOHs) 
(>40%) were observed in the 12q11-q13 and 12q22 regions, respectively [15]. Allelic 
losses of the 12q11-q13 and 12q22 regions were also detected in an additional genetic 
study of male GCTs [16]. In the Mitelman Database of Chromosome Aberrations in 
Cancer (http://cgap.nci.nih.gov/Catalog) a total of nineteen GCTs with 12q11-q13 
aberrations are listed, including seven cases with translocations, four cases with 
additions and six cases with deletions [17]. Interestingly, the 12q11-q13 abnormalities 
listed in the Mitelman Database, including those reported by Chaganti et al. [13-16] 
almost exclusively occur in non-seminomas or combined GCTs, with a highest 
incidence of teratomas (eight out of nineteen cases). Here, the positional cloning and 
molecular characterization of the t(8;12)(q23;q12)-associated breakpoint regions in a 
patient with an infantile sacral teratoma are presented. 
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MATERIALS AND METHODS 
 
Patient material and cell lines 
A male patient was diagnosed with a sacral teratoma at the age of 6 years. 
Subsequent cytogenetic analysis revealed the presence of a constitutional 
t(8;12)(q23;q12). A t(8;12)(q23;q12)-positive cell line was established after in vitro 
Epstein-Barr virus (EBV) transformation of patient-derived blood lymphocytes using 
standard procedures. Control lymphoblastoid cell lines were similarly derived from 
translocation-negative healthy donors. 
 
FISH analysis 
FISH analyses were carried out using routine procedures as described before [18;19]. 
Metaphase spreads from the t(8;12)(q23;q12)-positive lymphoblastoid cell line were 
hybridized with the following probes on 12q12-q13: RP11-815o9, RP11-609i23, RP11-
510p12, RP11-73b8, RP11-350f4 (BACPAC Resources, Oakland, USA), and on 8q23: 
RP11-79e1, RP11-91k1, RP11-79o20, RP11-79c21, RP11-80d8, RP11-79f7 (BACPAC 
Resources, Oakland, USA). Chromosome 8- and 12-specific centromeric probes were 
used for reference. A Zeiss epifluorescence microscope equipped with appropriate 
filters was used for visual examination of the slides. Digital images were captured 
using a high-performance cooled CCD camera (Photometrics) coupled to a 
Macintosh Quadra 950 computer and processed using the Oncor-image software 
(Gaithersburgh, MD, USA). 
 
Southern and Northern blot analyses 
DNA and RNA were isolated from the t(8;12)(q23;q12)-positive and control 
lymphoblastoid cell lines as described before [20]. Subsequently, the RNAs and 
DNAs were subjected to Southern and Northern blot analyses, respectively, using 
standard procedures [20]. For gene-specific breakpoint analysis, PCR fragments 
cloned into pGEMT vectors (Promega, Leiden, The Netherlands) were used as probes 
after labelling with [α-32P]dCTP by random priming. To this end, the following 
primer sets were employed:  
EIF3S6:  EIF3S6-exon1F; 5’CAAGATGGCGGAGTACGAC 3’, 
EIF3S6-exon13R; 5’ATCTTGAGTTGCCCAGTTAGG 3’. 
DKFZP434G1415: DKFZP434G1415F1; 5’ACCGAGGCACTGTTATAGAAG 3’, 
DKFZP434G1415R1; 5’GTCCATAGTAATTCACAAAGCC 3’. 
PTK9:   PTK9-F2; 5’GAGCAACTTGTGATTGGATC 3’, 
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PTK9-R1; 5’TTAAGGTCTTTCTGTCCCAC 3’. 
LOC51135/IRAK4:  LOC51135-F1; 5’AGGAATAGAAGATGAACAAACC 3’, 
LOC51135-R1; 5’GTGAACCTTCTTAATGTCTGG 3’. 
In addition, genomic PCR fragments generated by the following primer sets were 
used as probes for detailed analysis of the 8q23 breakpoint: 
Chr8-107:   Chr8-107F; 5’GCTGCCTTAAAACCATCGTC 3’, 
Chr8-107R; 5’GCCACTACTGTGGTGCACAT 3’. 
Chr8-105:  Chr8-105F; 5’ACAGAGTTTGAAGGCTAAGTGACG 3’, 
Chr8-105R; 5’GATTGACAATTTGGGCCACC 3’. 
 
Vectorette-PCR 
A vectorette-PCR procedure was employed essentially as described before [21], with 
minor modifications. Briefly, RsaI-digested DNA of the t(8;12)(q23;q12)-positive cell 
line was ligated o/n at 16°C to a phosphorylated Vectorette Top Strand Primer Blunt 
vector: (VTSP-blunt:  
5’CAAGGAGAGGACGCTGTCTGTCGAAGGTAAGGAACGGACGAGAGAAG 
GGAGAG3’) and a phosphorylated Vectorette Bottom Strand Primer vector (VBSP: 
5’CTCTCCCTTCTCGAATCGTAACCGTTCGTACGAGAATCGCTGTCCTCTCCTTG
3’). The resulting vectorette libraries were amplified in a hemi-nested PCR reaction, 
using a Universal Primer: 
UVP; 5’CGA ATC GTA ACC GTT CGT ACG AGA ATC GCT 3’, 
and sequence specific primers: 
8q23-vect1F; 5’TCCTTGACAGAGTTTGAAGGCTAAGTGACG 3’, 
8q23-vect2F; 5’TTGGATGCCCTGCCAAAGAACTTAGGATTG 3’. 
Subsequently, PCR fragments were separated on agarose gels, purified, ligated into a 
pGEMT vector (Promega, Leiden, The Netherlands), and sequenced. The genomic 
breakpoints were verified by PCR amplification using 12q12- and 8q23-specific 
primers:  12q12-1F; 5’TATGTGTTTTATCTCATGTGTGGC 3’, 
8q23-1R; 5’TTGACTCTCCTGGTGTTCAGTTCTAG 3’, 
8q23-1F;5’TCCTTGACAGAGTTTGAAGGCTAAGTGACG3’ and
 12q12-1R; 5’AATAATACATGGTGGCTAAGAG 3’, respectively. 
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RESULTS AND DISCUSSION 
 
Fine mapping of the constitutional t(8;12)(q23;q12) translocation 
Previously, we identified CEPH893a3 as the yeast artificial clone (YAC) that spans 
the t(8;12)(q23;q12)-associated breakpoint in 12q12 (previously assigned to 12q13; 
Fig. 1A) [12]. In order to further refine the 12q12 breakpoint region, a BAC contig 
was assembled that corresponds to this YAC. In addition, a BAC contig was selected 
within the 8q23 region for the characterization of the 8q23 breakpoint (Fig. 1B). FISH 
analysis on metaphase spreads of the t(8;12)(q23;q12)-positive cell line revealed that 
BAC clones RP11-815o9, RP11-609i23, RP11-510p12 and RP11-73b8 map proximal to 
the 12q12 breakpoint. BAC clone RP11-350f4 appeared to span the 12q12 breakpoint, 
as this clone hybridized, next to the normal chromosome 12, to both translocation 
derivative chromosomes der(8) and der(12). Similarly, BAC clones RP11-79e1, RP11-
91k1, RP11-79o20 and RP11-79c21 were found to map proximal, and RP11-79f7 distal 
to the 8q23 breakpoint, respectively. The intermediate BAC clone RP11-80d8 turned 
out to span the breakpoint in 8q23. This was again revealed by split FISH signals on 
both der(8) and der(12), next to a signal on normal chromosome 8 (Fig. 1C). 
RP11-350f4 (GenBank accession no. AC016143) is a completely sequenced BAC 
and measures 55 kb. According to the May 2004 freeze of the UCSC human genome 
browser this BAC contains one predicted gene of which the mRNA (BC068502) 
encodes a hypothetical protein (DKFZP434G1415). RP11-80d8 (GenBank accession 
no. AC083931) encompasses three unordered stretches of DNA that were assembled 
in the May 2004 freeze of the UCSC human genome browser based on the completely 
sequenced clones kb1153c10 (GenBank accession no. AP001331) and RP11-35g22 
(GenBank accession no. AC087620). Together, RP11-80d8 is approximately 152 kb in 
size and, as yet, it only contains one annotated gene, EIF3S6. This gene codes for the 
eukaryotic translation initiation factor 3 subunit 6, which binds to the 40S ribosome 
and promotes the binding of methionyl-tRNAi and mRNA. The EIF3S6 gene is also 
known as INT6 and, interestingly, its disruption by the mouse mammary tumour 
virus (MMTV) has been implicated in tumour development [22-24]. In addition, 
down-regulation of EIF3S6 has been observed in a considerable percentage of human 
breast and lung cancers [23]. 
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Figure 1. FISH mapping of the 12q12 and 8q23 breakpoints. A) Diagram depicting chromosome 
12, the 12q12 breakpoint-spanning CEPH YAC clone 893a3 and its corresponding BAC contig. In grey 
the breakpoint spanning clones (893a3 and RP11-350f4) are shown. B) Diagram depicting 
chromosome 8 and the selected BAC contig within 8q23, including the breakpoint-spanning BAC 
clone RP11-80d8 (grey). C) FISH analysis on a t(8;12)(q23;q12)-positive metaphase spread, using 
RP11-80d8 as a probe. Positive signals (green) are visible on the normal chromosome 8, der(8) and 
der(12). The centromere of chromosome 8 is marked in red and the chromosomes are 
counterstained with DAPI (blue). 
 
The 12q12 and 8q23 breakpoints map outside known genes 
Southern blot analysis was performed to examine whether the 12q12 and 8q23 
breakpoints disrupt one or both of the known candidate genes located on the 
breakpoint-spanning BAC clones RP11350f4 and RP1180d8, i.e., DKFZP434G1415 and 
EIF3S6, respectively. Therefore, RT-PCR fragments corresponding to these genes 
were labelled and hybridized to Southern blots containing cleaved DNAs extracted 
from the t(8;12)(q23;q12)-positive cell line and control cell lines derived from 
translocation-negative healthy donors. No aberrantly hybridizing fragments were 
detected on any of the blots containing different digests of the t(8;12)(q23;q12)-
positive cell line as compared to the control cell lines (not shown). 
Since the above selected probes only partially covered the breakpoint-
spanning BAC clones, additional probes were selected based on repeat-low 
sequences using the CENSOR database 
(http://www.girinst.org/Censor_Server.html) [25]. Using the chromosome 8-specific 
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PCR fragment Chr8-107F/R as a probe on Southern blots, wild-type fragments were 
detected in both BglII and AseI-digested DNAs extracted from the t(8;12)(q23;q12)-
positive and translocation-negative cell lines, as expected (Fig.2A: 7.5kb, 4.1kb and 
3.4 kb, respectively). In addition, aberrantly hybridizing fragments of 11kb and 2kb 
were readily detected in the BglII and AseI-digested DNAs extracted from the 
t(8;12)(q23;q12)-positive cell line, respectively, indicating that the 8q23 breakpoint 
must be located within these fragments. In addition, using the chromosome 8-specific 
PCR fragment Chr8-105F/R as a probe, an aberrantly hybridizing fragment of 1.2 kb 
was detected in the RsaI-digested DNA extracted from the t(8;12)(q23;q12)-positive 
cell line. By combining these data, we could narrow down the 8q23 breakpoint to a 
genomic interval of ~1 kb. 
Figure 2. Southern blot and vectorette-PCR analysis of the 8q23 breakpoint region. A) Southern 
blots containing BglII- AseI- and RsaI-digested genomic DNAs (upper panel) of the t(8;12)(q23;q12)-
positive cell line (lane 1) and a translocation-negative control cell line (lane 2), respectively, were 
hybridized with probe Chr8-107. Another Southern blot containing RsaI-digested DNA (lower panel) 
was hybridized with probe Chr8-105 (both PCR fragments). Next to the wild-type chromosome 8 
fragments (lane 1: 7.5 kb BglII fragment, 4.1 and 3.4 kb AseI-fragments, and 1 kb RsaI fragment) 
aberrantly hybridizing fragments are readily detected in the t(8;12)(q23;q12)-positive cell line (lane 
1: 11 kb BglII fragment, 2 kb AseI-fragment, and 1.2 kb RsaI fragment). B) Vectorette-PCR analysis 
using RsaI-digested genomic DNAs of the t(8;12)(q23;q12)-positive cell line (lane 1) and a 
translocation-negative control cell line (lane 2) as templates. A chromosome 8 wild-type fragment 
of 1 kb is present in both cell lines. In contrast, abnormally sized fragments of approximately 1.2 kb 
are present in the t(8;12)(q23;q12)-positive cell line 
 
In order to confirm the above Southern blot data and to determine the exact 
positions of both the 8q23 and 12q12 breakpoints, we set out to molecularly clone the 
respective breakpoints using vectorette-PCR. Therefore, specific primers 
corresponding to the 8q23-associated ~1 kb breakpoint interval were used in 
conjunction with vectorette primers and RSAI-digested DNAs extracted from the 
t(8;12)(q23;q12)-positive and translocation-negative cell lines. Completely in line with 
the Southern blot data, PCR fragments of ~1.2 kb were generated only from the 
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t(8;12)(q23;q12)-positive cell line, next to wild-type fragments of ~1 kb (Fig. 2B). 
Subsequent cloning and sequencing of this ~1.2 kb fragment indeed revealed a fusion 
of 8q23- and 12q12-derived genomic sequences (UCSC human genome browser, May 
2004 freeze). From the thus obtained exact mapping data we conclude that the 
breakpoint in 12q12 is located ~50kb downstream of the candidate gene 
DKFZP434G1415 and that the breakpoint in 8q23 is located ~13 kb upstream of the 
candidate gene EIF3S6 (Fig. 3A). In addition, we conclude that the 12q12 breakpoint 
is located ~130 kb upstream of ADAMTS20 and that the 8q23 breakpoint is located 
~183 kb upstream of KIAA0103, a putative gene that has been assigned to the 
neighbouring BAC clone RP11-79c21 (Fig. 1B and 3A). 
Figure 3. A) Diagram showing the 12q12 and 8q23 breakpoint-flanking BAC clones and their 
annotated genes. Directions of transcription are indicated by arrows and breakpoint-spanning BAC 
clones are marked in grey. B) Northern blot analysis of two translocation-negative control cell lines 
(lanes 1, 2) and the t(8;12)(q23;q12)-positive cell line (lane 3) using a EIF3S6-specific (exons 1-13) 
probe. For reference, the position of the 18S ribosomal RNA band is marked (arrowhead).  
 
The respective breakpoint positions were confirmed by direct PCR 
amplification on DNA extracted from the t(8;12)(q23;q12)-positive cell line, using 
12q12- and 8q23-specific primers. Subsequent cloning and sequencing of the 
reciprocal PCR fragments revealed that the translocation is balanced and that it is not 
associated with breakpoint-flanking deletions and/or duplications on either one of 
its derivative chromosomes. In addition, we examined whether the respective 
breakpoints were positioned within genomic regions that code for known 
microRNAs (miRNAs), using the May 2004 freeze of the UCSC human genome 
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browser. These miRNAs represent a novel class of small, functional non-coding 
RNAs of 19-23 nucleotides that are cleaved from precursors of ~60 to ~110 
nucleotides. They appear to be involved in several biological key processes such as 
cellular proliferation, death and stress resistance. Interestingly, recent literature has 
indicated that these miRNAs may be involved in tumourigenesis as well [26]. 
However, we found that the locations of both t(8;12)(q23;q12)-associated breakpoints 
were situated outside genomic regions that code for known miRNAs. 
 
Normal transcription of candidate genes in cell lines 
The t(8;12)(q23;q12)-associated breakpoints do not appear to disrupt any of the 
currently known annotated and/or predicted candidate genes present on the 
respective breakpoint-spanning BAC clones. However, the expression of these genes, 
and/or genes located further up- or down-stream of the breakpoints, may still be 
altered through position effects [27]. Therefore, we set out to determine the 
transcription levels of several of these candidate genes by Northern blot analysis. 
Since EIF3S6 is situated closest to the breakpoint in 8q23 and serves as an interesting 
candidate gene (see above), its transcription levels were first determined in 
t(8;12)(q23;q12)-positive and translocation-negative cell lines using a EIF3S6-specific 
probe (Fig. 3B). No significant differences were observed, suggesting that in these 
lymphoblastoid cell lines the breakpoint does not appear to affect the transcription 
level of EIF3S6. Similarly, the transcription levels of the 12q12-related genes PTK9 
and DKFZP434G1415 were determined. Again, no significant differences between the 
translocation-positive and -negative cell lines were observed (not shown). After 
similarly hybridizing the Northern blots with an IRAK4 probe, no transcripts could 
be detected in any of the cell lines tested. This latter finding may be due to a low 
expression level of this gene in lymphoblastoid cells. Unfortunately, no other tissues 
and/or tumour-derived samples of the patient were available for further analysis. 
Recently, we found that another gene located in the 12q12-q13 region, SENP1, 
was disrupted and fused to the MESDC2 gene in a patient with an infantile 
sacrococcygeal teratoma and a constitutional t(12;15)(q13;q25) [19;28]. Therefore, we 
examined the transcription level of SENP1 in the t(8;12)(q23;q12)-positive cell line as 
well. Again, no significant differences in transcription levels were detected between 
the t(8;12)(q23;q12)-positive and translocation-negative cell lines (not shown). 
In conclusion, we have detected a novel patient with an infantile sacral 
teratoma and a constitutional t(8;12)(q23;q12). Positional cloning of the breakpoints 
revealed that the translocation is balanced and that the respective breakpoints are 
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located upstream of the EIF3S6 gene in 8q23 and downstream of the 
DKFZP434G1415 gene in 12q12. The transcription levels of positional candidate 
genes were not significantly affected by the translocation breakpoints in the 
lymphopblastoid cell lines tested so far. Additional studies are required to establish 
whether the constitutional t(8;12)(q23;q12) has predisposed this patient to the 
development of the infantile sacral teratoma and, if so, whether this information will 
be instrumental for the elucidation of its underlying molecular mechanism(s). 
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ABSTRACT 
 
Despite the recent completion of the human genome project, the mapping of disease-
related chromosomal translocation breakpoints and genes has remained laborious. 
Here, we describe a novel and rapid procedure to map such translocation 
breakpoints using flow-sorted chromosomes in combination with array-based 
comparative genomic hybridization. To test the feasibility of this approach, we used 
a t(12;15)(q13;q25)-positive cell line with known breakpoint positions as a model. The 
derivative 12 chromosomes were flow sorted, labeled and hybridized to a genome-
wide array containing 3648 well-characterized human genomic clones. The exact 
locations of the breakpoints on both chromosome 12 and 15 could be determined in a 
single hybridization experiment. In addition, we have tested the minimal amount of 
material necessary to perform these experiments and show that it is possible to 
obtain highly reliable profiles using as little as 10,000 flow-sorted chromosomes. 
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INTRODUCTION 
 
There is ample evidence that recurrent chromosomal abnormalities, including 
translocations, are causally related to abnormal development and tumorigenesis. 
Indeed, the molecular characterization of translocation breakpoints has instrumented 
in the identification of disease causing genes and the subsequent elucidation of the 
underlying molecular defects. In cancer, for example, more than 100 recurring 
chromosomal translocations are known to trigger the activation of various oncogenes 
(http://www.ehgonline.net/translocation.pdf).  
Despite the fact that novel technologies have recently expedited the laborious 
process of positional cloning, such an approach still requires a considerable 
investment in time and reagents. Current methods may include chromosomal flow 
sorting, (reverse) painting, spectral karyotyping and/or fluorescent in situ 
hybridization (FISH) [1-4]. These technologies, however, lack the resolution required 
for a rapid identification of breakpoint spanning genomic sequences and/or genes. 
In order to overcome these limitations, and taking advantage of recent technological 
developments, we developed an alternative method. 
Here we show that rapid and reliable high-resolution breakpoint mapping is 
feasible, using a combination of chromosome flow sorting and array-based 
comparative genomic hybridization, employing a genome-wide array containing 
3648 genomic clones. As a proof of principle, we used a t(12;15)(q13;q25)-positive cell 
line with known breakpoint positions [5;6]. 
 
 
MATERIAL AND METHODS 
 
Cell culture and preparation  
A t(12;15)(q13;q25)-containing cell line was established by Epstein-Barr-virus-
transformation of peripheral blood lymphocytes, and cultured in RPMI 1640 medium 
supplemented with 10 % fetal calf serum, 2mM L-glutamine and antibiotics at 37°C 
in a humidified atmosphere containing 5% CO2. Cells in log phase were treated for 
16 hours with colcemid (0.05 mg/ml final concentration) in order to arrest cells in 
metaphase. Metaphase chromosomes were subsequently isolated for flow sorting as 
described previously [1].  
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Flow karyotyping and sorting  
Chromosomes were stained with Chromomycin-A3 (CA3) and Hoechst 33258 (Ho), 
and analyzed on a dual-laser beam flow cytometer (FACS-Vantage SE, Becton 
Dickinson, San Jose, Ca): CA3 was excited with an argon ion laser tuned at 458 nm at 
100 mW. CA3 fluorescence was measured through a 550-nm longpass filter. Ho was 
excited with an argon ion laser tuned into the UV range (351 and 364 nm) at 125-mW 
laser power. Ho fluorescence was measured through two KV 408 filters. The system 
was triggered on the CA3 fluorescence signal. In total, 300,000 chromosomes were 
sorted from each cluster (Figure 1) and subsequently purified using the QIAamp 
purification kit (QIAGEN, Hilden, Germany). DNA obtained in this way was used 
for array-based CGH analyses. Due to the fact that these small amounts of DNA 
cannot be measured accurately, we have based the number of chromosome copies on 
the number that is indicated by the FACS. 
 
Array-based comparative genomic hybridization (array CGH) 
Array CGH was performed essentially as described before [7;8] with minor 
modifications, including the production of a genome-wide BAC array, the use of an 
automated hybridization station and advanced normalization procedures [9]. In 
brief, the array used in this study contained 3648 colony-purified, FISH-verified, 
phage-tested BAC clones spotted in triplicate, most of which have been fully 
integrated in the human genome browser (http://genome.ucsc.edu/). 
Approximately 3000 of these clones cover the genome at a 1 Mb resolution. 
Additional clones included those mapping to known microdeletion hot-spots and to 
subtelomeric regions, as well as clones covering certain chromosome regions with a 
higher resolution than 1 Mb, including clones which were generated in the context of 
a previous positional cloning project performed on the cell line discussed in this 
paper [5]. The array CGH profile of the flow sorted chromosomes was established 
through hybridization of different amounts of cy3-dUTP labeled flow-sorted 
chromosomes combined with 500 ng cy5-dUTP labeled control genomic DNA. After 
scanning, fluorescence test over reference ratios were determined for each clone and, 
subsequently log2 transformed. These log2 ratios were centered to 0 by dividing the 
ratio for each clone by the mean of all ratios except for those mapping to the 
chromosomes 12 and 15. The latter approach was taken because there was hardly any 
signal in the cy3-channel for the clones not present on the derivative chromosome 12. 
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RESULTS AND DISCUSSION 
 
A t(12;15)(q13;q25)-positive cell line with previously characterized breakpoint 
positions [5;6] was used for FACS mediated flow sorting of the derivative 12 
chromosome [der(12)] and the normal chromosome 12 cluster (Figure 1). Due to the 
fact that the normal chromosome 12 overlaps with chromosomes 9, 10 and 11 in the 
flow karyogram, these chromosomes were sorted together. 
 
Figure 1. Flow-karyogram of the t(12;15)(q13;q25)-positive cell line. The circles mark the 
selected areas that were flow-sorted: the der(12) chromosome and the chromosome 12 cluster, 
including chromosomes 9,10 and 11.  
 
In an initial test we used 150,000 copies of the chromosome 9-12 cluster (test) 
labeled with cy3-dUTP in combination with 500 ng normal male genomic DNA 
(reference) labeled with cy5-dUTP and hybridized the mixture to the genome-wide 
BAC array. This pilot showed a marked hybridization of the clones mapping to the 
chromosomes 9-12 in the cy3 channel, whereas virtually no signals were measured 
for the clones mapping to the other chromosomes. Due to the fact that the normal 
cy5-labeled genomic reference DNA hybridized equally to all clones, the resulting 
log2-transformed test over reference values (log2 T/R values) for the clones mapping 
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to the chromosomes 9-12 varied between 2 and 3, whereas the clones mapping 
outside these chromosomes were centered around 0 (results not shown). This initial 
test showed that this procedure allows a quick identification of the precise 
chromosomal regions selected by flow sorting onto the genome wide BAC array. 
Furthermore, this test also indicates that less flow-sorted chromosomes might be 
used in these array experiments. Accordingly, hybridizations were performed with 
100,000 copies of der(12) labeled with cy3-dUTP (test) against 500 ng of normal male 
genomic DNA labeled with cy5-dUTP (reference) (Figure 2). The results showed a 
clear difference in T/R values between the clones that map to the der(12) and the 
clones that do not. The clones from 12pter through clone RP1-228p16 on 12q13.1 (48.4 
Mb) revealed a mean log2 T/R value of 3.8, whereas the clones from RP11-480h15 on 
12q13.1 (49.0 Mb) until 12qter displayed a log2 T/R value in the normal range (mean 
0) (Figure 2B). This result indicates that the breakpoint is positioned in the region 
encompassing RP1-228p16 and RP11-480h15 and correlates perfectly with our recent 
positional cloning efforts, which revealed that clone RP1-228p16 contains the 
breakpoint-spanning gene [5]. For chromosome 15 a similar pattern was observed, 
with a normal log2 T/R value for all clones from 15q12 through clone RP11-60j21 on 
15q25 (76.8 Mb), and a mean log2 T/R value of 4.1 for all clones from RP11-775c24 on 
15q25 (77.2 Mb) until 15qter (Figure 2C). Again this result perfectly matches our 
recent data indicating that RP11-775c24 contains the breakpoint-spanning gene on 
chromosome 15 [5]. 
In order to define the minimal amount of chromosomes that is necessary to 
acquire a reliable array CGH profile, 50,000 der(12), 10,000 der(12) and 1,000 der(12) 
copies were hybridized as test DNA together with 500 ng of reference DNA to our 
genome-wide chip. The results showed that hybridizations with 50,000 and 10,000 
derivative chromosomes gave profiles similar to Figure 2, whereas for 1,000 copies a 
clear-cut distinction between der(12) clones and non-der(12) clones was no longer 
possible. Therefore, the minimal amount of chromosome copies for a reliable array 
CGH profile lies in between 1,000 and 10,000 copies. The amount of 10.000 copies 
equals the chromosome copy number of autosomal chromosomes that are present in 
approximately 30 ng of genomic DNA from normal diploid human cells, assuming 
that a normal diploid human cell contains about 6 pg of DNA. Interestingly, in a 
typical array CGH experiment 500 ng of genomic DNA is routinely used. As an 
alternative for the use of even smaller numbers of flow-sorted chromosomes an 
amplification step may be included, as e.g. degenerate oligonucleotide primed (DOP) 
PCR (10,11). In a preliminary study we found that this approach is feasible using 
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1,000 copies as input in the PCR, although this needs further optimization (data not 
shown). Such amplifications may be required for other applications of this method, 
as for example delineation of the genomic content of unknown marker chromosomes 
in primary clinical samples. 
This study provides a further example of the power of the array CGH 
technology, which is rapidly becoming the method of choice for high-resolution 
screening of genomic copy number changes (8;12;13;14). Arrays with a genome-wide 
coverage at the 1-3 Mb resolution are becoming more readily available for these kind 
of applications (9;10;15). 
A novel method for rapid mapping of chromosomal translocation breakpoints 
based on a combination of chromosome flow sorting and array-based CGH was 
tested. As a proof of principle, derivative 12 chromosomes from a known 
t(12;15)(q13;q25)-positive cell line were flow-sorted and hybridized to a genome-
wide CHIP containing 3648 well characterized genomic clones. In a single 
hybridization experiment, using as little as 10,000 copies of the der(12) chromosome, 
the breakpoints at both chromosome 12 and 15 were fine-mapped, fully in line with 
our recent positional cloning studies (5). For chromosome 12 the breakpoint was 
positioned in the interval: RP1-228p16 to RP11-480h15 (~600 kb interval) and for 
chromosome 15 in the interval: RP11-60j21 to RP11-775-c24 (~400 kb interval). This 
method will greatly facilitate the tedious procedure of positional cloning from 
balanced chromosomal anomalies. Although we show the applicability of this 
approach using a cytogenetically characterized translocation this approach can be 
extended to all undefined complex chromosomal anomalies. The only prerequisite 
for using this approach is the necessity to be able to flow-sort aberrant chromosomes 
separately from their (supposedly) reciprocal translocation products. Currently, we 
are in the process of preparing a full coverage (32K) genome-wide CHIP 
(http://bacpac.chori.org/pHumanMinSet.htm). Once available, we will be able to 
map translocation breakpoints to a single BAC clone in a single experiment, leading 
to direct gene identification.  
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Figure 2. Mapping of the t(12;15)(q13;q25) by array-based CGH analysis. Profiles are shown after 
hybridization of 100,000 copies of der(12) (test), cy3-dUTP labeled, versus 500 ng of normal male 
genomic DNA (reference), cy5-dUTP labeled. Dark squares represent mean normalized T/R values 
for each clone in a log2 scale and the vertical lines represent the standard deviations of the 
replicates per clone. A) The T/R values of the genomic clones, ordered from chromosome 1 to Y, 
and within each chromosome by Mb position as presented in the June 2002 human genome assembly 
freeze. The vertical lines separate the clones per chromosome. A clear distinction can be made 
between the clones that hybridize to der(12) (with high T/R values) and the clones that do not (low 
T/R values). B) A zoom-in showing the T/R values of the chromosome 12 clones, ordered by Mb 
position. Indicated are the clones surrounding the breakpoint. C) T/R values of the chromosome 15 
clones, ordered by Mb position. Absence of clones from 0 to approximately 20 Mb is due to the 
difficulty of mapping, cloning and sequencing of this region. Indicated are the clones surrounding 
the breakpoint. 
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ABSTRACT 
 
Human germ cell tumors (GCTs) of neonates and infants constitute a heterogeneous 
group of neoplasms, including teratomas and yolk sac tumors with distinct clinical 
and epidemiologic features. As yet, little is known about the cytogenetic constitution 
of these tumors. We applied the recently developed genomewide array CGH 
technology to 24 germ cell tumors derived from patients under the age of 5 years. In 
addition, we included seven tumors derived from children and adolescents older 
than 5 years. In the series under the age of 5 years most teratomas displayed normal 
profiles, except for some minor recurrent aberrations. In contrast, the yolk sac tumors 
displayed recurrent losses of 1p35-pter, gains of 3p21-pter and gains of 20q13. In the 
GCTs of patients older than 5 years the main recurrent anomalies included gains of 
12p and gains of whole chromosomes 7 and 8. In addition, gains of 1q32-qter, losses 
of 6q24-qter and losses of 18q21-qter regions were frequently observed in GCTs with 
different histologies, independent of age. We conclude that array CGH serves as a 
highly suitable method for the identification of recurrent chromosomal anomalies in 
GCTs of neonates and infants. The recurrent anomalies point to chromosomal 
regions that may harbor novel diagnostic/prognostic identifiers and genes relevant 
for the development of these neoplasms. 
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INTRODUCTION 
 
Human germ cell tumors (GCTs) comprise a heterogeneous group of neoplasms 
exhibiting a high degree of epidemiologic, clinical, histologic and genetic diversity. 
They present at all ages, but are most frequently encountered as testicular GCTs in 
adolescent boys and young adult men. Previous genetic and epidemiologic studies 
have indicated that GCTs can be divided into four groups (1) teratomas and yolk sac 
tumors (YSTs) in neonates and infants, (2) GCTs of the adult testicular type, i.e., 
seminomas and non-seminomas, (3) dermoid cysts (mature cystic teratomas) of the 
ovary, and (4) spermatocytic seminomas in elderly men [5;18;22;30;45]. Several 
studies were aimed at identifying the precursor cells of these neoplasms and, 
although it is thought that most GCTs originate from germ cells, [29] suggested that 
extragonadal GCTs may originate from undifferentiated pluripotent stem cells. Other 
studies, however, have pointed at a cellular origin from transformed germ cells at 
different stages of development [3;28;33;35;38]. 
GCTs in adolescents and young adults primarily develop in the gonads, while 
the sacrococcygeal region is the main location for children under the age of 5 years 
[30]. Testicular GCTs in adult men with a teratoma component show almost always a 
malignant clinical course with metastatic spread. In contrast, (pure) mature 
teratomas in neonates and infants show clinical and histopathologic features of 
benign tumors, although they may recur after incomplete resection. 
 Two extensive epidemiologic studies among children with GCTs revealed 
that age is a critical factor for histology and prognosis. The median age of children 
who present with a teratoma is 5 months. Above this age, YSTs become more 
prevalent and risk-adapted chemotherapy in addition to surgical resection may 
become necessary [5;30]. A suitable clinical diagnostic marker for the presence of 
potentially malignant YST components is an elevated level of serum α-fetoprotein 
(AFP). However, clinical detection of YST may be hampered by physiologically 
elevated AFP levels during infancy [2]. Histologically, some neonatal teratomas 
contain YST foci that may be detected using immunohistochemistry [8;9;15].  
Testicular GCTs (group 2) have been studied most extensively at both the 
cytogenetic and the molecular levels. These studies revealed that, next to gross 
numerical and structural abnormalities, chromosome 12p sequences are 
overrepresented in almost all of these tumors, mostly due to the presence of one or 
more copies of an i(12p) chromosome. To date, i(12p) chromosomes and gain of the 
complete 12p arm have not been detected in GCTs of neonates and infants. Other 
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recurrent genomic aberrations in testicular GCTs of adults include 
overrepresentations of (parts of) chromosomes 7, 8, 12 and X, and under-
representations of (parts of) chromosomes 4, 5, 11, 13, 18 and Y [reviewed by 20]. As 
yet, little is known about the cytogenetic constitution of GCTs of neonates and 
infants. The sparsity of available information [reviewed by 40] indicates that in this 
patient group teratomas may be diploid with few, if any, cytogenetic aberrations 
[4;21;31]. In the malignant counterparts of these teratomas, i.e., YSTs, recurrent 
chromosomal aberrations have been observed, of which losses of the distal parts of 
1p and 6q and gains of 20q appear to be the most frequent ones [4;13;21;23-
25;31;32;36]. Based on their site of occurrence, histology, presumed origin, and 
cytogenetics, we and others have suggested that GCTs of neonates and infants 
constitute a distinct subgroup [22;24;25;30;33;36;40]. 
In this study we aimed at the identification of genomic regions that are 
recurrently affected in GCT subtypes of neonates and infants in order to (i) refine the 
diagnosis and prognosis of these subtypes and (ii) generate tools for the 
identification of disease-associated genes. We used the recently developed 
microarray-based comparative genomic hybridization (array CGH) technology that, 
due to its high resolution, has rapidly become the method of choice for the molecular 
cytogenetic analysis of inherited and acquired disorders, including GCTs 
[10;41;43;44;46]. 
 
 
MATERIALS AND METHODS 
 
Tumor samples 
In total 31 germ cell tumors (GCTs) of children under the age of 16 years were 
selected. These GCTs originated from different anatomic sites and presented with 
different histologies, mainly teratomas and yolk sac tumors (Table 1). The tumor 
samples were collected at the Department of Pathology, Erasmus MC (Rotterdam, 
The Netherlands) and the Department of Pathology, Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands). Additional tumor samples were 
derived from patients enrolled into a prospective trial for non-testicular GCTs in 
children (MAKEI 96, Düsseldorf, Germany). Fresh frozen tumor samples were 
characterized (histologically and morphologically) according to the MAKEI study 
guidelines [6] and F. Gonzalez-Crussi [7]. The samples were considered suitable for 
study when the percentage of tumor cells was > 80%, except for six cases which were 
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either micro- or macro-dissected. For micro-dissection laser-capture systems (Leica 
AS LMD or Arcturus Pixcell II) were used to isolate the tumor components from 
cases 5, 8, 10, 11 and 25 [1;39]. In one case (case 3) macro-dissection was used to 
separate stroma from tumor components. Genomic DNA was isolated using the 
QIAamp purification kit (QIAGEN, Hilden, Germany) and applied for array CGH. 
 
Array-based comparative genomic hybridization  
Array CGH was performed using a BAC microarray containing a total of 3569 
colony-purified FISH-verified clones, including approximately 3200 clones obtained 
through a collaboration with the Children’s Hospital Oakland Research Institute, 
BACPAC Resources (Oakland, CA) and other groups, to cover the genome with a 800 
kb resolution. This clone set represents a subset of a larger set that is currently being 
distributed by BACPAC Resources (http://bacpac.chori.org/). Our array has been 
extensively validated for the detection of copy number changes using normal versus 
normal control experiments as well as experiments in which cases with known 
micro-deletion syndromes were tested [42]. Details on BAC array preparation, probe 
labeling, hybridization, scanning and data analysis were also described by Vissers et 
al. [42]. In brief, equal amounts of patient and reference genomic DNAs were labeled 
by random priming with Cy3-dUTP or Cy5-dUTP. Labeled test and reference DNAs 
were mixed with Cot-1 DNA, co-precipitated and re-suspended in a hybridization 
solution. After denaturation of probe and target DNAs, hybridization and post 
hybridization washing procedures were performed using a GeneTac Hybridization 
Station (Genomic Solutions, Camebrigeshire, UK), according to the instructions of the 
manufacturer. Fluorescence intensity images were acquired using an Affymetrix 428 
scanner, and analyzed by Genepix Pro 5.1 (Axon Instruments Inc., Foster City, CA). 
For each spot the median pixel intensity minus the median local background for both 
dyes were used to obtain a genomic copy number ratio. Data normalization was 
performed by using the software package SAS version 8.0 (SAS Institute, Cary, NC) 
per array subgrid by applying lowess curve fitting to predict the log2 transformed 
test over reference (T/R) values. All mapping information regarding clone locations, 
cytogenetic bands, and genomic contents were retrieved from the UCSC genome 
browser (April 2003/May 2004 freezes). 
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Table 1. Characterization of Germ Cell Tumors 
aIn years. 
bCopy number changes of genome regions in several BAC clones, depicted by chromosome bands, chromosomes 
arms, or whole chromosomes. 
cEmbryonal carcinoma, yolk sac tumor, teratoma. 
dEncompassing three BAC clones. 
 
RESULTS 
 
Patient classification and array CGH analysis 
Genomic DNA extracted from 24 GCTs of neonates and infants (0-5 years old) were 
analyzed with the array CGH technique for the presence of copy number alterations. 
Based on their histology, these tumors were subdivided into two subgroups (Table 
1): subgroup 1 consisting of 16 teratomas (mature as well as immature types) and 
subgroup 2 consisting of eight yolk sac tumors (YSTs). Additionally, we included a 
Case
Sub-
group Age
a
Sex Site Histology Copy number losses
b
Copy number gains
b
1 1 <1  m sacrococcygeal mat. teratoma
2 1 <1  f sacrococcygeal mat. teratoma
3 1 <1  f sacrococcygeal mat. teratoma (14q11)
d
4 1 <1  f sacrococcygeal mat. teratoma
5 1 <1  m testis mat.+ im. teratoma
6 1 <1  f sacrococcygeal mat. teratoma
7 1 <1  m retroperitoneal mat. teratoma
8 1 <1  m sacrococcygeal mat.+ im. teratoma
9 1 <1  f sacrococcygeal mat. teratoma 12p
10 1 <1  m testis mat. teratoma
11 1 <1  f neck mat.+ im. teratoma
12 1 <1  f sacrococcygeal mat.+ im. teratoma 20p 20q
13 1 2 m sacrococcygeal mat. teratoma
14 1 1 m sacrococcygeal mat. teratoma
15 1 <1  m kidney im. teratoma
16 1 <1  m sacrococcygeal im. teratoma 18, 20p 19
17 2 <1  m sacrococcygeal yolk sac tumor 1p22-p31, 12p, 14q32-qter, 
15q25, 18q21-qter
16p13-pter, 19, 20q
18 2 1 f sacrococcygeal yolk sac tumor
19 2 1 f uterus/vagina yolk sac tumor 1p35-pter, 6q22-qter, 18q 20q13-qter
20 2 1 m testis yolk sac tumor 5, 6, 8 1q, 12p, 19q13-qter, 
21 2 1 m testis yolk sac tumor 1p35-pter, 1p22-p31, (4p13)
d
, 
7q11, 16p, 19, 20p
3p21-pter, (5q35)
d
, 20q
22 2 2 f sacrococcygeal yolk sac tumor 6q22-qter, 13pter-q21, 15q25 1q, 3p21-pter, 20q
23 2 3 m mediastinum yolk sac tumor 1p35-pter, 4q21-q28, 5q12-
q14, 8p,18p11-pter, 20p
3p21-pter, (7q11)
d
, 20q
24 2 3 f sacrococcygeal yolk sac tumor 1p35-pter, 6q24-qter, 18q21-
qter, 19, 21q22-qter
1q, 20q
25 3 6 f sacrococcygeal im. teratoma 6q16-qter 1q24-qter, 12
26 3 7 f ovary mixed tumor
c 18q 7,8, 12p, 19
27 3 8 f ovary mat. teratoma
28 3 11 f ovary mat. teratoma 12p
29 3 11 f ovary dysgerminoma 18q 1q, 7,8, 10, 12p13-
pter, 12p11, 19, 21
30 3 12 f ovary im. teratoma 7,8, 12p, 21
31 3 16 f pelvis  yolk sac tumor 1p, 4, 6q, 7q32-qter,  8p, 13 1q, 6p, 17q, 20q
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third cohort of seven GCTs derived from patients above the age of 5 (range: 6-16 
years) with different histologies, i.e., four teratomas, one YST, one dysgerminoma, 
and one mixed GCT with embryonal carcinoma, YST and teratoma components 
(subgroup 3). Most tumors from subgroups 1 and 2 originated from the 
sacrococcygeal region, whereas most tumors from the third subgroup originated 
from the ovary (Table 1). 
The genomewide microarray that we used contained 3569 BAC clones 
(spotted in triplicate) covering the entire human genome. Since sex-matches are 
required for the retrieval of reliable X/Y data, we only analyzed the clones mapping 
to the autosomes. Differentially labeled patient and normal control DNAs were 
hybridized to the arrays, whereas two sex-matched and four sex-mismatched normal 
versus normal hybridizations were included as controls. Figure 1 shows 
representative array CGH profiles of tumor samples selected from each subgroup. 
Note the differences between these three profiles: an almost normal profile in a 
teratoma of the first subgroup (Fig. 1A), multiple copy number changes including 
loss of 1p, loss of 20p and gain of 20q in a YST of the second subgroup (Fig. 1B), and 
multiple copy number changes including gain of 12p in a mixed GCT of the third 
subgroup (Fig. 1C). 
 
 
 
Table 2. Recurrent Copy Number Changes of Genomic Regions >5 Mb 
aDetermined by the minimal region of overlap. bClones that flank the minimal region of overlap. 
Gain/loss Chromosome band
a
Flanking clones
b Size (Mb) Subgroup 1 Subgroup 2 Subgroup 3
Gain 1q32-qter RP11-155f3-CTB-167k11 43 0 3 3
Gain 3p21-pter RP11-91p19-RP5-1186b18 47 0 3 0
Gain chr. 7 159 0 0 3
Gain chr. 8 146 0 0 3
Gain 12p13-pter RP11-174g6-CTB-124k20 15 0 0 5
Gain 12p11 RP11-38f11-RP11-78f16 2 0 0 5
Gain 19q13-qter RP11-2j15-qter 12 1 2 2
Gain 20q13 RP11-1e23-RP11-124d1 11 1 7 1
Loss 1p35-pter RP11-4p6-CTC-232b23 33 0 4 1
Loss 6q24-qter RP11-40o24-RP1-57h24 22 0 4 2
Loss 8p11-pter RP11-210f15-RP11-91j19 37 0 2 1
Loss 18q21-qter RP11-43k24-RP5-964m9 30 1 3 2
Loss 20p12 RP11-51o4-RP11-149o7 10 2 2 0
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Figure 1. Genomic profiles of three germ cell tumors. Dark squares represent mean normalized 
T/R values for each clone in a log2 scale. The log2 T/R values of the genomic clones are ordered 
from chromosome 1 to 22, and within each chromosome by Mb position as presented in the UCSC 
genome browser (April 2003 freeze). The vertical dotted lines separate the clones per chromosome. 
A) An example of a subgroup 1 profile; a sacrococcygeal teratoma of a baby boy (case 1). Note the 
single deleted clone on 5p15 (RP11-88l18). B) An example of a subgroup 2 profile; a mediastinal yolk 
sac tumor of a 3 year old boy (case 23) with loss of 1pter-p35 and gain of 3pter-p21 and 20q. C) An 
example of a subgroup 3 profile, an ovarian mixed germ cell tumor of a 7 year old girl (case 26) with 
the typical gain on 12p co-occurring with a number of other imbalances; gain of chromosomes 7, 8 
and 19 and loss of 18q. 
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Array CGH profiles in infantile teratomas 
Most teratomas of subgroup 1 showed normal array CGH profiles, independent of 
the tumor location (Table 1). In three cases (9, 12 and 16; Table 1) DNA copy number 
variations were detected. Interestingly, one of these profiles (case 12) again showed 
loss of 20p and gain of 20q (Fig. 2A). This observation suggests the presence of an 
i(20q) chromosome in this tumor sample. In addition, 20p is deleted in the profile of 
case 16, next to loss of chromosome 18 and gain of chromosome 19. The profile of 
case 9 showed loss of a complete 12p arm. Figure 3A displays a frequency plot of 
copy number changes in subgroup 1 based on the percentages of gains (log2 T/R 
>0.3) and losses (log2 T/R <-0.3) measured for each individual BAC clone on the 
array. Except for a few isolated clones, no recurrent gross (>5 Mb) copy number 
changes could be detected for this subgroup (Table 2). In contrast, small genomic 
regions (<5Mb) were frequently found to be imbalanced. In Table 3 the BAC clones 
are listed that showed gains or losses in at least four of the array CGH profiles 
(including subgroups 1, 2 and 3) and that did not coincide with the recurrent gross 
genomic changes presented in Table 2.  
 
 
Figure 2. Examples of the most frequent gross copy number changes. A) Chromosome 20 profile 
of a sacroccocygeal teratoma (case 12). B) Chromosome 1 profile of the infantile YST (case 24) 
showing the smallest region of overlap of the 1pter-p35. C) Chromosome 1 profile of the infantile 
YST (case 21) with a somatic (region 1) and a constitutional (region 2) deletion on 1p. D) 
Chromosome 12 profile of an ovarian mixed GCT (case 26).  
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Recurrent genomic aberrations in infantile yolk sac tumors 
The genomic profiles of infantile YSTs (subgroup 2) revealed several frequently 
occurring gross (>5 Mb) chromosomal alterations (Fig. 3B). Seven cases showed gains 
and/or losses of multiple large chromosomal regions, and one case appeared to 
exhibit a normal profile (Table 1). The following recurrent gross aberrations (listed in 
Table 2) were detected in three or more cases: (1) loss of 1p35-1pter. This region was 
lost in four of eight cases, with the shortest region of deletion overlap in a 
sacrococcygeal YST from a 3-year-old girl (Fig. 2B; case 24, 33 Mb); (2) gain of 1q32-
qter in three cases, with the shortest region of amplification overlap determined by 
the same case as that for the 1p35-pter region (Fig. 2B; case 24, 43 Mb); (3) gain of 
3p21-pter, again observed in three of the cases, all of which showing amplified 
regions of similar size, the shortest region of overlap being 47 Mb; (4) loss of 6q24-
qter in four cases, of which one profile showed loss of a complete chromosome 6 and 
with the shortest region of deletion overlap determined by case 24 (22 Mb); (5) loss of 
18q21-qter in three cases, with the minimal region of deletion overlap (30 Mb) 
determined by cases 19 and 24; (6) gain of the complete or partial 20q arm, the most 
frequently observed anomaly in the infantile YSTs, with gain of 20q13 in seven of 
eight cases and the shortest region of overlap, 11 Mb, determined by case 19. Other, 
less frequent (< 3 cases), copy number changes in this subgroup were loss of 8p, loss 
of 15q25, gain of 19q13-qter, loss of 19 and loss of 20p (Table 1).  
 
Loss of 1p35-pter in a yolk sac tumor and a constitutional del(1)(1p22-1p31) 
Subgroup 2 included a testicular YST of a 1-year-old boy (case 21) whose array CGH 
profile revealed two 1p regions with genomic loss (Fig. 2C, regions 1 and 2). This was 
confirmed by a replicate array CGH experiment and an independently performed 
whole-chromosome CGH analysis (not shown). One of these regions overlapped 
with the 1p35-pter region that was frequently found to be deleted in the samples of 
subgroup 2 (see above). The other region mapped to 1p22-p31. In addition, this boy 
suffered from mental retardation. Through conventional cytogenetic analysis of 
blood lymphocytes, a constitutional mosaicism for the del(1)(p22p31) was detected 
(not shown). The boundaries of the constitutional deletion were determined by BAC 
clones RP11-451c22 and RP11-114k16, encompassing a ~10-Mb region. Interestingly, 
loss of this region was also detected in one of the other infantile YSTs (subgroup 2; 
case 17) and it contains 49 genes, including those encoding MSH4 (involved in 
meiotic recombination), AK5 (adenylate kinase 5), FUBP1 (binds MYC promoter), 
PRKACB (kinase, catalytic subunit of AMPK), DLAD (DNase II beta), SPATA1 
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(spermatogenesis associated 1), SSX2IP (SSX2 interacting protein), NYD-SP29 (a 
presumed testis development protein), BCL10 (B-cell CLL/lymphoma 10) and 
CYR61 (promotes angiogenesis, cell adhesion, cell proliferation and chemotaxis).  
 
Table 3. Recurrent Copy Number Changes of Genomic Regions <5 Mb 
Gain/loss Clone name
Chromosome 
band
Subgroup 
1
Subgroup 
2
Subgroup 
3 Genes
a
LCV
e 
detected
Gain CTB-172i13 and 
RP5-1011o17
2qter 4 0 1 - B
Gain RP11-89a12 3p14.1 2 2 2 TAFA1 -
Gain RP11-554b18 3p12.1 3 1 2 - -
Gain RP11-80h24 3p12.1 3 0 1 - -
Gain RP11-91a15 3p11 2 1 1 EPHA3 -
Gain RP11-40d5 4q28 1 3 0 - -
Gain RP11-467a2 5q13.2 3 0 1 TNPO1 -
Gain RP11-17o4 9q34 4 1 1 AK130729 -
Gain RP11-88n14 14q21 2 1 2 - B
Gain RP1-149d14 17p11 2 4 2 - -
Loss RP11-11m9 4p15 1 1 3 - -
Loss RP11-82m24 5p15 1 1 2 - -
Loss RP11-29n3 5p15 1 1 2 CTNND2 -
Loss RP11-135M13 5p15 0 1 3 FBXL7 -
Loss RP11-88l18 5p15 9 3 4 - B
Loss CTD-2041d13 5q13 1 3 2 several genes
b A
Loss RP11-121g20 6p21 1 3 0 several genes
c -
Loss RP11-4o1 9q31 1 1 2 SUSD1 -
Loss RP11-95j4 9q32 3 2 3 - -
Loss RP11-180c18 10p15 2 1 1 ADARB2 -
Loss RP11-115g22 15q13 3 0 1 CHRNA7 A
Loss RP11-33b6 15q24 2 0 3 ARIH1, GOLGA6, BBS4 -
Loss RP11-368n21 16p11 1 2 2 several genes
d -
Loss RP11-348E16 18q11 1 1 3 RBBP8 -
Loss RP11-19l3 18q21 2 0 2 AK127467 -
Loss RP11-135L16 22q13 0 3 2 PARVB, PARVG, AK074042, 
AB051431 
-
Loss RP11-93F4 22q13 2 1 1 TRMT1, GTSE1, CELSR1 -
 
aBased on the UCSC humane genome browser (May 2004 freeze). 
bX83301, AK130833, SERF1A, SMN1, SMN2, BIRC1, GTF2H2. 
cCAPN11, BC062989, c6orf110, AL353957, SLC29A1, HSPCB, SLC35B2, NFKBIE, AK130739, AARSL, MGC33600, 
AK126839, AL833884, SPATS1. 
dAK023827, LAT1-3TM, AF271775, BC062756, SPN, QPRT. 
eLarge-scale copy number variations (LCVs), presented as such in (A) Sebat et al. [34] and/or (B) Iafrate et al. 
[14]. 
  
Chapter 6 
 100
 
Figure 3. Overview of the genomewide frequency of copy number changes. The percentage of 
copy number gains in black (log2 T/R >0.3) and losses in grey (log2 T/R <-0.3) from chromosome 1 
to 22 ordered by Mb position as presented in the UCSC genome browser (April 2003 freeze). A) 
Overview of the infantile GCT profiles with a teratoma histology (age < 5 years); subgroup1. B) 
Overview of the infantile GCT profiles with a yolk sac histology (age < 5 years); subgroup2. C) 
Overview of the GCT profiles derived from children above the age of 5 years with mixed histology; 
subgroup3. From this figure it is clear that these groups differ markedly in their number of 
abnormalities as well as the genomic regions involved. 
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Recurrent genomic aberrations in GCTs from children over 5 years old 
The array CGH profiles of the older patients (subgroup 3; >5 years) again revealed 
gross recurrent genomic abnormalities (Fig. 3C). Four out of seven cases showed 
anomalies encompassing multiple large genomic regions. Two cases showed profiles 
with only one or three gross genomic aberrations and in one case the profile 
appeared to be normal (Table 1). The most prevalent abnormality was gain of 
chromosome 12p (present in five out of seven cases; Fig. 3C and 2D). Four of the 
profiles showed gain of the complete 12p arm (cases 25, 26, 28 and 30), whereas in 
one case (case 29) copy number gains were detected in two distinct regions on 12p 
(12p13-pter (15 Mb) and 12p11 (2 Mb), respectively). 
Another gross recurrent copy number change was gain of 1q32-qter, observed 
in three out of seven cases. Copy number loss of (a part of) 6q was detected in two 
cases, gains of the entire chromosomes 7 and 8 in three cases, loss of 18q in two cases, 
gain of a complete chromosome 19 in two cases and gain of a complete chromosome 
21 in two cases. 
 
 
DISCUSSION 
 
We used the recently array CGH technique to analyze 24 archival GCTs from 
children under the age of 5 years, which we divided into two subgroups based on 
histology (teratoma, subgroup 1; and YST, subgroup 2). In addition, seven GCTs of 
patients older than 5 years were included (subgroup 3). The 5-year age cut-off was 
chosen on basis of previous studies that showed a clear age distribution in germ cell 
tumors with respect to histology and tumor location [5;30]. The aim of this study was 
to obtain detailed information on the cytogenetic constitution of the different GCTs 
of neonates and infants in order to (i) identify recurrent chromosomal aberrations 
with diagnostic and/or prognostic implications and (ii) identify genomic regions that 
may harbor genes relevant to tumor formation.  
In agreement with the results of previous cytogenetic and conventional CGH 
studies, we found no gross anomalies in most of the teratoma-derived profiles 
(subgroup 1). In contrast, most YST-derived profiles (subgroup 2) showed gross 
recurrent copy number changes. These recurrent changes included losses of 1p 
(1p35-pter), gains of 1q (1q32-qter), gains of 3p (3p21-pter), losses of 6q (6q24-qter), 
losses of 18q (18q21-qter) and gains of 20q (20q13), all of which had been detected 
previously [13;21;25;33]. Losses of (distal parts of) 1p and 6q were considered the 
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most prevalent genomic aberrations in YSTs of neonates and infants. We detected 
losses of the distal parts of 1p (1p35-pter) in half these cases. A similar percentage 
was found in an ongoing independent LOH study, which includes one of the present 
cases (case 24). One patient (case 21) with a YST exhibited a constitutional 1p22-p31 
deletion next to a somatic 1p35-pter deletion in the tumor. In addition, the patient 
was mentally retarded and the constitutional deletion may be causally related to the 
mental status of this patient. This deletion may also have acted as a predisposing 
factor for YST development in this patient. This idea was supported by a similar loss 
of 1p21-p31 in three infantile YST cases described previously [21] and one additional 
case of subgroup 2 with a 1p22-p31 deletion in this study. The most prevalent 
anomaly in subgroup 2 was gain of (parts of) 20q with a shortest region of overlap of 
11 Mb at 20q13, containing multiple genes (~90). Gain of 20q or 20q11-q13 is a 
common anomaly in human cancers [12;16] and has also been reported in GCTs, both 
in the adult and infantile types [19;21;24;31]. In contrast, such chromosome 20 
anomalies were not noted in a large cytogenetic study of childhood GCTs [4]. This 
may be a results of the experimental limitations, i.e., an i(20q) chromosome can easily 
be overlooked by conventional cytogenetic analyses. Interestingly, gain of 20q and 
loss of 20p was also observed in a teratoma profile of a tumor that contained both 
teratoma and YST components (case 12).  
Subgroup 3 (> 5 years) showed heterogeneous profiles, with gain of (parts of) 
12p as main aberration (5 of 7 cases). Gain of (parts of) 12p together with gain of the 
complete chromosomes 7 and 8 were observed in three cases. These chromosomal 
anomalies are common in adult testicular GCTs (group 2; see introduction [20] and 
have also been detected in several malignant ovarian GCTs [17;26;37]. As most GCTs 
from children older than 5 years in this study were ovarian GCTs, our data support 
the hypothesis that ovarian and testicular GCTs may share a common pathogenic 
pathway. In accordance with the literature, the two minimal regions of 
overrepresentation on chromosome 12p mapped to 12p13-pter and 12p11, 
respectively [11;27;46;]. So far, gain of a part of 12p has only rarely been observed in 
neonatal or infantile GCTs [21]. In line with these observations, gain of 12p was 
detected only once (case 20) in the GCTs under the age of 5 years (subgroups 1 and 2) 
in this study.  
Two profiles of the third subgroup resembled profiles of subgroup 1 and 2. 
Similar to the profiles of subgroup 1, the profile of an ovarian teratoma of an 8 year 
old showed no gross aberrations (case 27). The array CGH profile of a pelvic YST 
from a 16-year-old male patient (case 31) resembled the infantile or neonatal YST 
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profiles in several aspects, including loss of 1p35-pter, loss of 6q and gain of 20q. No 
gain of 12p was observed. Together, these observations suggest that this tumor may 
actually fit into subgroup 2. Notably, this patient had suffered from a sacrococcygeal 
YST during infancy. Therefore, the tumor examined in the present study can be 
considered a metachronous secondary tumor. Unfortunately, no material of the 
primary tumor was available for analysis. Nevertheless, this observation indicates 
that some tumor components that reflect the childhood type of GCT may have 
persisted until the metachronous tumor manifested itself. The fact that the array 
CGH profile diverts from the profile that should be considered appropriate for the 
patient’s age, strongly supports that GCTs that develop during infancy are 
biologically distinct from those that develop during adulthood. Gains of (parts of) 1q, 
losses of (parts of) 6q and losses of (parts of) 18q were detected in profiles of tumors 
from both subgroup 2 and 3, implying that these regions may be related to the 
pathogenesis of GCTs in both these subgroups. 
In addition to the gross recurrent copy number changes discussed above, 
some novel small regions (< 5 Mb) encompassing one or a few BACs, showed 
recurrent copy number alterations (Table 3). Some of these regions were affected 
only in specific subgroups, including 2qter and 9q34 in teratomas (subgroup 1), 4q28 
and 6p21 in YSTs (subgroup 2) and 4p15, 15q24 and 18q11 in GCTs of children older 
than age 5 (subgroup 3). Other regions showed gains or losses in all GCT subgroups, 
including regions on 5p15, 5q13, 9q32, 17p11 and 22q13. Recently, it was found that 
large-scale copy number variations (LCVs, encompassing 100 Kb or more) may 
significantly contribute to the array of naturally occurring genomic polymorphisms 
[14;34]. On the basis of this information, we evaluated whether the recurrent 
anomalies detected in this study coincided with any of the LCVs reported in the 
previous articles. Indeed, we found that several of the small regions presented in 
Table 3 were described as such, including those on 2qter, 5p15, 5q13. In reverse, the 
other recurrent anomalies that we detected may represent tumor-related copy 
number changes. 
Taken together, we have concluded that genomewide array CGH technology 
is highly suitable for the detection of recurrent genomic anomalies in GCTs of 
neonates and infants. This study confirmed data from previous studies indicating 
that most neonatal and infantile teratomas do not exhibit gross genomic aberrations. 
Furthermore, we concluded that the genomes of the GCTs differ markedly between 
the two age-groups as presented here. For neonatal and infantile YSTs, regions 
20q13, 1p35-pter and 3p21-pter and individual BAC clone regions may harbor novel 
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diagnostic/prognostic identifiers and genes relevant to the development of these 
neoplasms.  
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GENERAL DISCUSSION  
 
Many human tumours are characterized by non-random chromosomal aberrations 
[1]. These aberrations have been instrumental for (i) improvement of diagnosis and 
prognosis of various tumour (sub)types [2;3] and (ii) to gain insight in the genetic 
mechanisms that underlie the development of different tumour (sub)types [4;5]. 
Moreover, in some cases detailed (cyto)genetic knowledge has resulted in the design 
and subsequent clinical application of efficient and specifically targeted cancer 
therapies [6;7]. Tumour-associated chromosomal aberrations may occur as 
inherited/constitutional anomalies or as anomalies that are somatically acquired by 
(precursor) cells during the processes of tumour initiation and/or progression. Also 
in human germ cell tumours (GCTs), non-random chromosomal aberrations have 
been documented [8]. Until recently, however, only limited information was 
available on the (cyto)genetic constitution of neonatal and infantile GCTs [chapter 1, 
[9-15]. In this thesis, both constitutional and acquired chromosomal aberrations were 
studied aiming at the identification of diagnostic/prognostic identifiers and genes 
that play a role in the development of this latter group of GCTs. To this end, 
advanced positional cloning and microarray-based genomic profiling strategies were 
used. 
 
Constitutional aberrations 
The 12q11-q13 region has been suggested as a candidate region that may harbour one 
or more genes relevant for the development of GCTs [16-18]. Interestingly, this 
region was also involved in two constitutional chromosome translocations in patients 
with infantile GCTs: t(12;15)(q13;q25) and t(8;12)(q23;q12), respectively. Therefore, 
we set out to positionally clone the breakpoints and genes associated with these 
translocations [chapters 2, 3 and 4].  
As a result of the constitutional t(12;15)(q13;q25) translocation, the SENP1 
gene on chromosome 12 and the MESDC2 gene on chromosome 15 were disrupted 
and fused [chapter 3]. Both reciprocal fusion genes were present and transcribed in 
the tumour cells and their open reading frames predicted aberrant proteins. Current 
knowledge on the function of wild-type SENP1 indicates that this protein can modify 
the precursor form of the small ubiquitin-related modifier 1 (SUMO-1) and can de-
conjugate mature SUMO-1 from its target proteins [19-22]. Although in vitro studies 
have shown that SENP1 can function as a SUMO-2 and SUMO-3 protease as well 
[20;22], a recent mouse study indicated that SENP1 primarily acts as a SUMO-1 
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protease [19]. As yet, it is unknown whether SENP1 can also act as a protease for 
SUMO-4 [23]. The recent mouse study also revealed that SENP1 plays a critical role 
during embryogenesis, i.e., a homozygous retroviral insertion into the first intron of 
the mouse ortholog of SENP1 (SuPr-2) caused a 50-fold reduction in SuPr-2 
transcription and an increase in sumoylated proteins and unprocessed SUMO-1. 
Together, these anomalies resulted in an embryonic lethal phenotype due to 
placental failure [19]. SUMO-1 is a post-translational modifier and, depending on the 
affected target protein, this modification may alter its sub-cellular localization, its 
activity, its stability and/or its protein-protein interaction network [24;25]. 
Consequently, these modifications may affect various cellular key processes, 
including regulation of transcription, maintenance of genome integrity and/or signal 
transduction. In chapter 3 we showed that the two MESDC2-SENP1 derived SENP1 
proteins (MESEs) are still able to desumoylate target proteins such as PML in a 
desumoylation assay. Recently, other groups showed that, next to PML, SENP1 is 
also able to deconjugate SUMO-1 from HDAC1 [26], ERM [27], SF1 [28], C-Jun [29] 
and IE1 [20]. It is expected that in the future more SENP1 target proteins will be 
added to this still growing list. Therefore, we assume that SENP1 may affect a 
plethora of cellular processes. Based on the MESDC2-SENP1-associated promoter 
swap [chapter 3], we suggest that the normal spatio-temporal expression pattern of 
SENP1 may have been altered in the patient. However, it remains to be established 
which cellular processes were altered, and how these altered processes contributed to 
the development of the infantile GCT. Additional support for a putative role of 
sentrin-specific proteases in tumour development comes from two recent findings: (i) 
one of the SENP family members, SENP6, is also disrupted and fused to a gene 
(TCBA1) in the lymphoma-derived cell line HT1 [30] and (ii) SENP1 may be involved 
in thyroid oncocytic adenomas [31]. 
Transient expression studies showed that MESD (the MESDC2 mouse 
homolog) acts as an ER chaperone for several LDL receptors, including the WNT co-
receptors LRP5 and LRP6 [32;33]. In addition, MESD null mutations led to an 
embryonic lethal phenotype, resulting from a lack of primitive streak formation and 
mesoderm induction due to defective patterning of the proximal epiblast [32;34;35]. 
Hsieh et al. suggested that this patterning defect might be caused by anomalous 
WNT signalling resulting from an incorrect intracellular routing of the LRP5 and 
LRP6 co-receptors [32]. This hypothesis was supported by a recent study in which 
LRP5/LRP6 double knockout mice exhibited similar phenotypic features as MESD 
mutant mice [36]. We found that the t(12;15)(q13;q25)-associated N-terminally 
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truncated MESDC2 protein (SEME) is no longer targeted to the intracellular ER 
compartment [chapter 3], indicating that this protein may have lost its capacity to act 
as an ER chaperone for the LDL receptor family members. During embryonic 
development, germ cells originate from the proximal epiblast [chapter 1], a structure 
that showed a patterning defect in the MESD mutant mice. Based on these 
observations and the finding that one MESDC2 wild-type allele is still present in the 
tumour cells [chapters 2 and 3], we suggest that MESDC2 haplo-insufficiency and/or 
anomalous subcellular localization of SEME proteins may lead to an abnormal 
development and/or routing of uncommitted primordial germ cells, the presumed 
precursors of infantile GCTs.  
At the chromosome architectural level, it is of interest to note that SENP1 is 
located within the FRA12A region on chromosome 12 [37]. FRA12A is a rare, folate-
sensitive fragile site that coincides with YAC clone 919G8, which contains SENP1 
next to 41 other genes [37, chapter 2]. As fragile sites are prone to DNA double-
strand break formation, FRA12A may underlie the occurrence of the t(12;15)(q13;q25) 
translocation. Previously, fragile sites have been suggested to be involved in the 
pathogenesis of human tumours [38;39]. A well-known example of the latter is 
FRA3B, a fragile site that coincides with the FHIT gene which is disrupted by the 
familial renal cell carcinoma-associated t(3;8)(p14;q24) translocation [39]. So far, 
however, no association with tumour development and FRA12A has been 
documented. FRA12A has been associated with mental retardation and congenital 
anomalies, including some distinct dysmorphic facial features [reviewed in 37]. It 
should be noted that, next to the GCT, the t(12;15)(q13;q25)-positive patient also 
showed some dysmorphic features, including an upward slant and obesitas [chapter 
2]. Although these latter features do not overlap with those mentioned above, it 
cannot be excluded that the constitutional t(12;15)(q13;q25) may have contributed to 
the occurrence of these dysmorphic features. 
The chromosome 12 breakpoint of the constitutional t(8;12)(q23;q12) 
translocation appeared to map in a region that, as yet, is devoid of any annotated 
genes and/or known miRNA-coding sequences (May 2004 freeze of the UCSC 
human genome browser) [chapter 4]. Moreover, this breakpoint maps ~4 Mb from 
the SENP1 gene, which indicates that SENP1 may not be affected by the 
t(8;12)(q23;q12) translocation. This idea was substantiated by our preliminary 
transcription assays, which failed to show any significant differences between 
t(8;12)(q23;q12)-positive and -negative cells. Similar to the 12q12 breakpoint, the 8q23 
breakpoint was mapped outside known genes and/or miRNA-coding sequences, 
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and our preliminary transcription data again suggested that positional candidate 
genes flanking the breakpoints are not affected. However, the possibility remains 
that t(8;12)(q23;q12) may affect the expression of more distant genes and/or 
regulatory elements that may play a role in the initiation/progression of the infantile 
GCT. 
As a result of the Humane Genome Project, several new technologies were 
developed that may facilitate the search for positional candidate genes. One of these 
technologies is microarray-based comparative genomic hybridization (array CGH) 
[40;41]. We used array CGH in combination with flow-sorted derivative 12 
chromosomes to map the t(12;15)(q13;q25)-associated breakpoints in a single 
hybridization experiment. By doing so, we found that the results obtained [chapter 5] 
fully correspond to those obtained through our positional cloning efforts [chapter 3], 
thereby indicating that this novel integrated array CGH technology serves as a very 
efficient high-throughput tool to map chromosomal aberrations and to identify its 
associated candidate genes. 
 
Acquired aberrations 
At the start of this thesis-work (cyto)genetic information on neonatal and infantile 
GCTs was scarce [chapter 1]. Therefore, a detailed analysis was initiated to screen 
this group of GCTs for the presence of acquired chromosomal aberrations using the 
array CGH technology [chapter 6]. Such aberrations may (i) serve as 
diagnostic/prognostic identifiers and (ii) point at regions harbouring genes 
underlying the development of these tumours. The GCTs included in our study were 
classified as type I according to the criteria outlined in chapter 1 [8;42]. Among these 
GCTs, a subgroup consisting of yolk sac tumours (YSTs) exhibited recurrent losses of 
1p35-pter and 6q24-qter and recurrent gains of 1q32-qter, 3p21-pter and 20q13. 
Similar data were reported by others in type I YSTs using alternative methods such 
as conventional karyotyping and/or conventional chromosomal CGH [9-15]. In 
contrast to the YSTs, a subgroup of type I teratomas failed to exhibit any gross 
recurrent genomic aberrations, even after detailed analysis with our genome-wide 
BAC arrays [chapter 6]. This result agrees with several other studies reported to date 
[9;10;13-15] and may explain why these tumours usually behave in a benign fashion 
and rarely progress to malignancy. Instead, minute genetic alterations, epigenetic 
changes and/or microenvironmental factors (stroma) may play a role in the 
development of these teratomas. Currently, this latter option is being investigated by 
several groups for different tumour types, including GCTs [43-45]. Microsatellite 
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analysis showed that the stroma cells adjacent to metastatic mature type II teratomas 
(after chemotherapy) may exhibit similar genomic anomalies as the tumour 
component itself, suggesting that these stroma cells may actually be derived from the 
same progenitor cells [46]. In the constitutional t(12;15)(q13;q25)-positive infantile 
GCT (see above), a YST component was present next to a teratoma component. By 
using array CGH we found that this tumour, next to the translocation, exhibited a 
gain of 20q and a loss of 20p [chapter 6, case 12]. As gain of 20q was also detected in 
almost all infantile/neonatal YSTs [chapter 6], we speculate that the chromosome 20 
anomalies observed in the former case may reflect the development of a malignant 
endodermal sinus (YST) component (i.e., tumour progession). 
Type II GCTs exhibit genomic profiles distinct from those observed in the type 
I GCTs. An overview of the most frequent recurrent genomic aberrations 
encountered in these two types of GCTs is depicted in Table 1. Some aberrations, 
however, were detected in both tumour types, i.e., gains of (parts of) 1q, and losses of 
(parts of) 1p, 6q and 18q, although we found that type I GCTs exhibited relatively 
higher percentages of losses of (parts of) 1p and 6q (in ~50% of the type I GCTs 
studied). Also, an occasional type I YST showed gain of (a part of) 12p (notably 
12p13) [chapter 6; see also 10].  
 
Table 1. Recurrent genomic aberrations in type I and II GCTs. The recurrent aberrations in type I 
GCTs were based on chapter 6 and [9-15], and those in type II GCTs were based on a recent review 
of Oosterhuis et al. [8]. 
YST = yolk sac tumour, TE = teratoma, SE = seminoma, NS = non-seminoma. 
 
Some of the recurrent genomic anomalies [Table 1] are not restricted to GCTs 
but also occur in other, distinct, tumour types. This latter observation suggests that 
the genomic regions involved may harbour genes that affect a broader spectrum of 
target tissues, or reflect unstable regions that are prone to chromosomal aberrations. 
In addition, some of the recurrent genomic anomalies that we detected in the type I 
GCTs, i.e., loss of 1p36 and gain of 20q13, have also been associated with advanced 
Type of GCT
Histological 
component
Copy number losses Copy number gains
YST 1p, 4(q), 6q 1q, 3(p), 20q 
TE - -
Type II
SE, NS (including 
YST and TE)
1p, 11, 13, 18 and Y 7,8, 12p, 21 and X
Type I 
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stages of tumour development [47-51]. Therefore, these regions may harbour 
progression-related genes (see also above).  
Based on occurrence, clinical outcome, histology and genetic constitution we 
[chapter 1 and 6] and others [11;42;52;53] have suggested that neonatal/infantile 
GCTs may constitute a distinct pathogenic subgroup. This hypothesis was further 
substantiated by the genomic profiles that we observed in the subgroup of GCTs 
above the age of 5 years [chapter 6]. Based on Table 1, these profiles suggest a mix of 
type I and type II GCTs. Compared to testicular type II GCTs (> 15 years), ovarian 
type II GCTs usually occur at a younger age (> 4 years) [chapter 1 and [8;42]. As the 
above-described GCT subgroup mainly consisted of ovarian GCTs, this might 
explain the mix of type I and type II GCTs within this subgroup (> 5 years). The 
recurrent aberrations as depicted in Table 1 may, therefore, serve as additional 
diagnostic tools for this subgroup. Taken together, we conclude that array-based 
genomic profiles may serve as excellent diagnostic/prognostic identifiers for 
neonatal and infantile GCTs and, in addition, may point at genomic regions that may 
harbour genes [see chapter 6] relevant for the initiation and/or progression of these 
tumours. 
 
Future prospects  
Through the constitutional t(12;15)(q13;q25) two novel candidate genes, SENP1 and 
MESDC2, were identified that, as a result of their disruption and fusion, may have 
contributed to the development of the infantile GCT. Obviously, additional studies 
are required (i) to clarify the role of the respective fusion genes in the development of 
this GCT, and (ii) to assess whether the genes involved play a role in the 
development of sporadic GCTs and/or normal germ cells. Such information may 
also explain why other family members carrying the same constitutional 
translocation did not develop any GCT. In order to assess the role of SENP1 and 
MESDC2 in sporadic GCTs, we suggest a screening of multiple tumour samples for 
mutations, copy number changes and aberrant expression patterns, including those 
of downstream targets. For analyses at the protein level, the availability of suitable 
antibodies, tumour samples and matched normal control tissues will be essential. 
Type I GCTs are complex tumours capable of forming highly differentiated 
structures, resembling embryogenesis in several aspects. Studies in mice revealed 
that disturbances in germ cell development during embryogenesis may predispose to 
GCTs [54-56]. In order to completely comprehend the development of type I GCTs 
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from a precursor cell to a full blown tumour an integrated multi-disciplinary 
approach is suggested. Such an approach would include studies on (i) factors 
involved in formation, routing and homing of normal germ cells and in re-
programming these cells, (ii) DNA, mRNA and protein constitution of various 
tumour stages, and (iii) interactions of the surrounding tissues with tumour cells 
and/or their precursors. Several of these approaches have already been initiated, 
including studies on normal germ cell development [57, for review], imprinting 
studies to search for the progenitor cell [13] and the (cyto)genetic studies [chapter 6 
and 9-15], including our array CGH study in which we analyzed the type I GCT 
genome at a 1 Mb resolution [chapter 6]. Over the past few years the microarray 
technology has rapidly evolved and several new applications are becoming available 
[58] that, e.g., will provide ploidy information at a high resolution. These include (i) 
32k BAC arrays with a tiling-path resolution of the complete human genome [59;60], 
(ii) SNP arrays that allow a detailed screening for the presence of uniparental 
disomies, polymorphisms and copy number changes that may predispose to GCT 
development [61], and (iii) various oligonucleotide arrays that allow high resolution 
DNA copy number and/or gene expression analysis [62-64]. Additionally, high-
density cDNA or oligonucleotide arrays can be used for simultaneous, integrated 
analyses of expression and genomic anomalies [64-67]. For all above assays the 
availability of well-defined and well-preserved tissues and/or cells is crucial, next to 
matched control tissues and/or cells for reference. Once defined, candidate genes can 
be tested for their role in the initiation and/or progression of type I GCTs using cell- 
and animal model systems. For these purposes, several suitable mouse models are 
currently available [55;56;68-70] and reviewed in [8]. Since these mice develop 
teratomas that closely resemble human type I teratomas, they may be of particular 
relevance for unravelling the in vivo process of type I GCT development. 
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Figure 4 (chapter 2). A) Diagram showing: chromosome 12, a series of q13.1 markers and the 
corresponding CEPH YACs. B) FISH analysis with YAC 919-G-8 on a lymphocyte derived metaphase 
spread from the patient. Positive signals (green) on both der(12) and der(15) and on the normal 
chromosome 12 are indicated. Chromosomes are shown in red. 
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Figure 5 (chapter 3). Subcellular localization of A) MESDC2 and B) SEME, using C-terminal VSV 
tags and SV40 promoters, after transient expression in HeLa cells. The proteins were visualized 
using an anti-VSV antibody (green; left panels). Endogenous PDI, an ER resident protein, was 
visualized with an anti-PDI antibody (red; middle panels). Overlays are shown in the right panels. 
 
 
Figure 1 (chapter 4). FISH mapping of the 12q12 and 8q23 breakpoints. A) Diagram depicting 
chromosome 12, the 12q12 breakpoint-spanning CEPH YAC clone 893a3 and its corresponding BAC 
contig. In grey the breakpoint spanning clones (893a3 and RP11-350f4) are shown. B) Diagram 
depicting chromosome 8 and the selected BAC contig within 8q23, including the breakpoint-spanning 
BAC clone RP11-80d8 (grey). C) FISH analysis on a t(8;12)(q23;q12)-positive metaphase spread, using 
RP11-80d8 as a probe. Positive signals (green) are visible on the normal chromosome 8, der(8) and 
der(12). The centromere of chromosome 8 is marked in red and the chromosomes are 
counterstained with DAPI (blue). 
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SUMMARY  
 
Human germ cell tumours (GCTs) can be classified into five distinct types, based on 
differences in anatomical location, histology, clinical outcome, age and genotype 
(chapter 1). The first type, the type I GCTs primarily occur in neonates and infants 
under the age of five years and include teratomas and yolk sac tumours with distinct 
clinical and epidemiologic features. Until recently, the type I GCTs were poorly 
characterised at the genetic level.  
The objectives of this thesis were (i) to identify candidate genes involved in the 
development of type I GCTs and (ii) to identify chromosomal anomalies that may 
serve as diagnostic/prognostic markers for this tumour type. To these ends, we 
positionally cloned two constitutional chromosome translocations in patients with 
type I GCTs and breakpoints in the 12q11-q13 region, a region thought to harbour 
one or more genes involved in GCT development. In addition, we analysed a 
selected series of sporadic type I GCTs for the presence of recurrent chromosomal 
anomalies using a microarray-based comparative genomic hybridisation (array 
CGH) technology. 
In chapter 2 clinical and cytogenetic data are reported of a novel case with an 
infantile sacral teratoma and a constitutional t(12;15)(q13;q25). Loss of heterozygosity 
analysis revealed that both translocation-derived chromosomes were retained in the 
patient's tumour. In addition, we assembled a 12q13 genomic contig that spans the 
breakpoint. This genomic contig served as a starting point for the final elucidation of 
the translocation breakpoint-associated sequences. In chapter 3 the positional cloning 
of the 12q13 and 15q25 breakpoints is described in further detail. This effort resulted 
in the identification of two breakpoint-spanning genes: the SUMO/Sentrin-specific 
protease 1 gene SENP1 on chromosome 12 and the embryonic polarity-related 
mesoderm development gene MESDC2 on chromosome 15. In addition, we found 
that through the translocation both genes were disrupted and fused. The resulting 
reciprocal SENP1-MESDC2 (SEME) and MESDC2-SENP1 (MESE) fusion genes were 
transcribed in tumour-derived cells and their open reading frames encode aberrant 
proteins. The translocation-associated SEME protein contained most of the MESDC2 
protein sequence except for the N-terminal part, which includes the signal peptide. 
This explains why, in contrast to wild-type MESDC2, SEME is no longer targeted to 
the endoplasmatic reticulum, thereby leading to a presumed loss of function as a 
chaperone for the WNT co-receptors LRP5 and/or LRP6. Wild-type SENP1 is a 
protease that can cleave SUMO-1 from its substrates and pre-process the precursor 
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form of SUMO-1, a post-translational modifier that plays an important role in several 
cellular key processes. The translocation-associated MESE proteins, containing 
almost the complete protein sequence of SENP1, were found to exhibit 
desumoylation capacities similar to those observed for wild-type SENP1, as assessed 
by using a PML desumoylation assay. From these results we hypothesize that a 
disturbed function of MESDC2 (SEME), MESDC2 haplo-insufficiency and/or spatio-
temporal disturbances in desumoylating activities during critical stages of embryonic 
development might have predisposed the patient to the development of its teratoma 
(chapters 3 and 7).  
In chapter 4 we reported the positional cloning of a second 12q11-q13-
associated breakpoint in a patient with a type I GCT (sacral teratoma) and a 
constitutional t(8;12)(q23;q12). The 12q12 breakpoint appeared to be located ~50kb 
downstream of the DKFZP434G1415 gene and ~4 Mb upstream of the SENP1 gene. 
The 8q23 breakpoint was subsequently found to be located ~13 kb upstream of the 
EIF3S6 gene. Preliminary expression analyses revealed that the transcription levels of 
several positional candidate genes, including DKFZP434G1415, SENP1 and EIF3S6, 
were not significantly affected by the translocation. As yet, however, it cannot be 
excluded that these translocation breakpoints affect the expression of more distant 
genes and/or regulatory elements that may have played a role in the development of 
the sacral teratoma.  
In chapter 5 a novel and rapid procedure is presented for the mapping of 
genomic translocation breakpoints using flow sorted chromosomes in combination 
with array CGH. To test the feasibility of this approach, the t(12;15)(q13;q25)-positive 
cell line described in chapter 3 was used as a model. The derivative 12 chromosomes 
were flow sorted, labelled and hybridized to a genome-wide array containing 3.6 
thousand well-characterized human genomic clones. By doing so, we found that in a 
single hybridization experiment the genomic locations of the breakpoints on both 
chromosomes 12 and 15 could be determined. The array CGH data obtained were in 
complete accordance with those reported in chapter 3.  
In order to gain further insight into the genetic constitution of type I GCTs, we 
applied array CGH to 24 GCTs derived from patients under the age of 5 years and 7 
GCTs from patients above the age of 5 years (chapter 6). Three subgroups were 
defined that could be distinguished by their genomic profiles: 1) teratomas of 
patients at ages <5 years displaying normal profiles, except for some minor recurrent 
aberrations, 2) yolk sac tumours of patients at ages <5 years displaying recurrent 
losses of 1p35–pter and gains of 3p21–pter and of 20q13 and 3) GCTs of patients at 
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ages > 5 years displaying recurrent gains of 12p, chromosomes 7 and 8. Independent 
of age and histology, gains of the 1q32–qter region and losses of the 6q24–qter and 
18q21–qter regions were frequent events in these GCTs. From these results we 
conclude that array-based genomic profiles may be used as excellent 
diagnostic/prognostic identifiers for type I GCTs.  In addition, these profiles point at 
genomic regions that may harbour genes relevant for the initiation and/or 
progression of these tumours (chapters 6 and 7). 
Next to the above-mentioned results and conclusions, some future prospects 
are discussed in chapter 7. We propose that the development of type I GCTs may be 
elucidated by using a multi-disciplinary approach, including the analysis of normal 
germ cells, neoplastic germ cells and tissue environmental interactions of both these 
cells. 
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Humane kiemceltumoren (KCTen) kunnen op basis van verschillen in anatomische 
locatie, histologie, klinisch verloop, leeftijd en genotype ingedeeld worden in 5 
groepen (hoofdstuk 1). De eerste groep, de type I KCTen, zijn zeldzame tumoren die 
voornamelijk voorkomen bij pasgeborenen en kinderen tot vijf jaar. Histologisch 
gezien bestaat deze groep uit teratomen en dooierzaktumoren, met onderlinge 
klinische en epidemiologische verschillen. Teratomen zijn relatief goedaardige 
tumoren, waarin gedifferentieerde structuren als bot-, haar- en tandstructuren 
kunnen voorkomen. Dooierzaktumoren hebben een grotere neiging tot uitzaaien en 
vertonen minder differentiatie dan teratomen. Tot voor kort was nog niet veel 
bekend over de genetische samenstelling van de type I KCTen. 
De doelstellingen van dit proefschrift waren (i) het opsporen van kandidaat-
genen die mogelijk een rol spelen bij het ontstaan en/of de ontwikkeling van type I 
KCTen en (ii) het identificeren van chromosomale afwijkingen die als diagnostische 
/prognostische parameters zouden kunnen dienen voor dit tumortype. Daartoe 
werden twee constitutionele chromosomale translocaties in kaart gebracht in 
patiënten met type I KCTen. De translocaties van beide patiënten lieten breuken in 
12q11-q13 zien, een chromosomaal gebied waarvan verondersteld wordt dat deze 
een of meer genen bevat voor KCT ontwikkeling. Daarnaast werd een groep 
sporadische type I KCTen geselecteerd en met behulp van array CGH onderzocht op 
het voorkomen van frequente chromosomale afwijkingen. 
In hoofdstuk 2 werden de klinische en cytogenetische data van een kind met 
een sacraal teratoom en een constitutionele t(12;15)(q13;q25) beschreven. Beide 
translocatie-geassocieerde chromosomen bleken behouden te zijn in de tumor. 
Verder werden in dit hoofdstuk genomische fragmenten geïdentificeerd die het 
breukpunt in het 12q13 gebied omspannen. Deze fragmenten werden als startpunt 
gebruikt voor de definitieve opheldering van de DNA sequenties waarin de 
translocatie breukpunten zich bevinden. De positionele klonering van de 12q13 en 
15q25 breukpunten werd in detail beschreven in hoofdstuk 3. Dit resulteerde in de 
identificatie van twee breukpunt-omspannende genen: het SUMO/Sentrin-specifieke 
protease 1 gen SENP1 op chromosoom 12 en het polariteit-gerelateerde mesoderm 
ontwikkelingsgen MESDC2 op chromosoom 15. Door de translocatie bleken beide 
genen gebroken en aan elkaar gefuseerd te zijn. De resulterende SENP1-MESDC2 
(SEME) en MESDC2-SENP1 (MESE) fusiegenen kwamen tot expressie in de 
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tumorcellen en coderen voor afwijkende eiwitten. Het translocatie-geassocieerde 
SEME eiwit bevat een groot deel van de MESDC2 eiwitsequentie, behalve het N-
terminale deel dat het signaalpeptide bevat. Dit verklaart waarom, in tegenstelling 
tot het wildtype MESDC2, SEME niet in het endoplasmatisch reticulum terecht komt. 
Deze afwijkende locatie zou mogelijk kunnen leiden tot een verlies van de functie 
van het SEME eiwit als chaperonne voor de WNT receptors LRP5 en/of LRP6. 
Wildtype SENP1 is een protease dat 1) SUMO-1 kan afklieven van zijn 
substraateiwitten en 2) de voorloper van SUMO-1 kan modificeren. SUMO-1 is een 
post-translationele modificeerder die een belangrijke rol speelt in verschillende 
essentiële cellulaire processen. De translocatie-geassocieerde MESE eiwitten bevatten 
bijna de gehele sequentie van SENP1. Uit een PML desumoyleringsanalyse bleek dat 
de MESE eiwitten vergelijkbare desumoylerings-capaciteiten bezitten als het 
wildtype SENP1 eiwit. Op basis van bovenstaande resultaten stellen wij voor dat 
tijdens kritische fases van de embryonale ontwikkeling een verstoorde functie van 
MESDC2 (SEME), MESDC2 haplo-insufficiëntie en/of spatio-temporele verstoringen 
in desumoylerings-activiteiten mogelijk hebben geleid tot de ontwikkeling van het 
teratoom bij de patiënt (hoofdstukken 3 en 7). 
In hoofdstuk 4 werd de positionele klonering beschreven van een tweede 
12q11-q13-geassocieerde breuk in een patiënt met een type I KCT (sacraal teratoom) 
en een constitutionele t(8;12)(q23;q12). Het 12q12 breukpunt bleek ~50 Kb distaal van 
het DKFZP434G1415 gen en ~4 Mb proximaal van het SENP1 gen te liggen. Het 8q23 
breukpunt kon vervolgens worden gelokaliseerd en bleek ~13 Kb proximaal van het 
EIF3S6 gen te liggen. Voorlopige expressie analyses lieten zien dat de transcriptie 
niveaus van verschillende positionele kandidaat-genen, waaronder DKFZP434G1415, 
SENP1 en EIF3S6, niet significant beïnvloed werden door de translocatie. Op dit 
moment kan niet worden uitgesloten dat de translocatie de expressie heeft beïnvloed 
van andere verderop gelegen genen en/of hun regulatoire elementen en, via deze 
weg, de ontwikkeling van het sacrale teratoom. 
In hoofdstuk 5 werd een nieuwe en snelle manier voorgesteld om genomische 
translocatie-breupunten te lokaliseren met behulp van gesorteerde chromosomen in 
combinatie met de array CGH techniek. Om de effectiviteit van deze methode te 
testen werd de t(12;15)(q13;q25)-positieve cellijn uit hoofdstuk 3 gebruikt als model. 
De derivaat 12 chromosomen werden gesorteerd, gelabeld en gehybridiseerd op een 
genoomwijde array met daarop 3.6 duizend goed gekarakteriseerde humane 
genomische clones. Op deze manier werd vastgesteld dat één hybridisatie 
experiment voldoende is om de breukpunten op zowel chromosoom 12 als 
Samenvatting 
 
134
chromosoom 15 exact te bepalen. De array CGH data kwamen volledig overeen met 
de data zoals gerapporteerd in hoofdstuk 3. 
Om meer inzicht te krijgen in de genetische samenstelling van type I KCTen 
werden vierentwintig van deze tumoren uit patiënten onder de 5 jaar en zeven van 
deze tumoren uit patiënten boven de 5 jaar geanalyseerd met behulp van de array 
CGH techniek (hoofdstuk 6). Daarbij werden drie subgroepen gedefinieerd die 
onderscheiden konden worden op basis van hun genomische profielen: 1) teratomen 
van patiënten onder de 5 jaar met normale profielen, op een paar kleine 
terugkomende afwijkingen na, 2) dooierzaktumoren van patiënten onder de 5 jaar 
met de volgende frequente afwijkingen: verlies van 1p35-pter en winst van 3p21-pter 
en 20q13 en 3) tumoren van patiënten boven de 5 jaar met frequente winst van 12p en 
de chromosomen 7 en 8. Verder werd geconstateerd dat, onafhankelijk van leeftijd of 
histologie, winst van 1q32-qter en verlies van 6q24-qter en 18q21-qter frequente 
afwijkingen zijn in deze KCTen. Op basis van deze gegevens hebben we 
geconcludeerd dat genomische array CGH profielen geschikt zijn voor het 
identificeren van diagnostische en/of prognostische markers voor de type I KCTen 
en dat deze profielen duiden op genomische regio’s die genen kunnen bevatten die 
relevant zijn voor de initiatie en/of progressie van deze tumoren.  
Naast de bovengenoemde resultaten en conclusies werden in hoofdstuk 7 
enkele toekomstperspectieven besproken, met als aanbeveling om de ontwikkeling 
van type I KCTen te bestuderen via een multidisciplinaire aanpak. Een dergelijke 
aanpak zou de analyse van normale kiemcellen, ontaarde kiemcellen en de 
interacties tussen normale cellen, tumorcellen en hun omliggende weefsels kunnen 
omvatten. 
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DANKWOORD 
 
De laatste woorden staan op papier, het boekje is af!  
Dit is het moment om iedereen te bedanken die mij op een of andere manier heeft 
geholpen en er mede voor heeft gezorgd dat het boekje is zoals het nu is.  
 
Ad Geurts van Kessel, mijn promotor, wil ik als eerste bedanken voor de zinvolle 
discussies, het razendsnelle nakijken van manuscripten en de vrijheid die je me gaf 
om me wetenschappelijk en persoonlijk te ontwikkelen. Het steuntje in de rug in het 
begin van mijn promotieonderzoek heeft er toe bijgedragen dat ik doorgezet heb en 
uiteindelijk beide breukpunten in kaart heb gebracht, ook hiervoor bedankt! 
 
Han Brunner, bedankt dat ik onderzoek mocht doen op jouw afdeling. Al zal het 
tussen-de-middag schaatsen er niet meer bij zijn, graag hoor ik wanneer het ijs in 
Nijmegen weer dik genoeg is! Eric Schoenmakers (EricS) bedankt voor jouw inbreng, 
al je ideeën en praktische tips. Martien van Asseldonk, al ben je maar even mijn 
begeleider geweest, jou wil ik bedanken voor je hulp tijdens de beginfase van mijn 
promotieonderzoek: een goed begin is het halve werk. 
 
Halverwege mijn promotieonderzoek kwam jij, Lilian Vreede, het kiemceltumor-
‘groepje’ uitbreiden. Je hebt bergen werk verzet, je was altijd super georganiseerd en 
een goede discussiepartner. Bovenal was het erg gezellig om met jou samen te 
werken, bedankt voor alles!  
 
Het researchlab van Cytogenetica, waar ik al die tijd heb gewerkt wil ik bedanken 
voor alle praktische tips, kritische vragen, gezellige film en spel avondjes en de 
goede sfeer op het lab. In de loop van de tijd hebben er verschillende mensen 
gewerkt: Anita, AnkeD, AnkeR, Daniëlle, Diederik, Ellen, ErikH, Helma, Jan, José, 
Marc, Marga, Marieke, Marjan, Monique, Nuno, Roland, Ron. Van de FISH en Chips: 
Corine, Gerard, Huub, Irene (bedankt voor al je hulp met de arrays!), Judith, Lisenka, 
Rolph, Simon, Walter. Bert, jij bedankt voor het maken van de hybride cellijnen; in 
die tijd een must voor het ophelderen van chromosomale breukpunten. 
 
Verder wil ik uiteraard de hele afdeling Antropogenetica bedanken. In de loop van 
de tijd hebben verschillende mensen mij geholpen met praktische zaken, 
computerproblemen, tips, en ideeën. Ook de gezellige uitjes, lunchdates en nog veel 
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meer hebben natuurlijk meegeholpen aan een goed verloop van mijn 
promotieonderzoek, allemaal bedankt!  
 
Naast de (ex)collega’s van Antropogenetica zijn er verschillende mensen binnen en 
buiten Nijmegen waarmee ik met veel plezier heb samengewerkt en daarvoor wil 
bedanken. 
 
Leendert Looijenga, jou wil ik bedanken voor het feit dat ik altijd even kon e-mailen 
of komen overleggen als ik met een specifieke kiemceltumor-vraag zat. Onze 
samenwerking heeft dan ook geresulteerd in een paar mooie artikelen. En omdat er 
nog genoeg vragen overblijven, doet het me goed dat ik in jouw groep verder kan 
werken aan de kiemceltumoren. Tevens wil ik jou en Wolter Oosterhuis bedanken 
voor onze discussie in het begin van mijn promotieonderzoek; uiteindelijk heeft dit 
hoofdstuk 6 opgeleverd. Van mijn huidige lab wil ik ook Hans Stoop, Ad Gillis en 
Ruud van Gurp bedanken voor kleuringen, microdissecties en DNA en RNA 
isolaties.  
 
Dominik Schneider, vielen Dank für die Bereitstellung der Patientenproben und die 
angenehme Kooperation. Ich freue mich, dass wir auch in Zukunft weiter zusammen 
arbeiten werden. Switching from German to English, I would like to thank Dr. Yeh, 
who allowed me to do some ‘SENP1’ work in his lab. Also, I would like to thank 
Jinke Cheng for his help in the lab. Sometimes my ‘Dutch-English’ and your 
‘Chinese-English’ did not completely match, but finally we always understood each 
other, so also thanks for your patience!  
 
Christine Hulsbergen-van de Kaa, bedankt voor het uitzoeken van de verschillende 
Nijmeegse kiemceltumoren en Henry Dijkman voor je hulp bij de microdissecties. 
Jack Fransen wil ik bedanken voor zijn hulp met de confocale microscoop. 
 
Voor het informeren over de t(12;15)(q13;q25) en het ter beschikking stellen van 
patiëntmateriaal bedank ik Lutgarde Govaerts, Cokkie Wouters, Rosalyn Slater and 
Jan van Hemel. For referring the t(8;12)(q23;q12) to us and for providing patient 
material, I thank Louise Strong and Harry Drabkin. 
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Naast collega’s zijn er mijn vrienden en familie die ik bedank voor al jullie steun en 
vooral jullie begrip in de afgelopen periode wanneer ik weer eens aan mijn boekje 
moest werken.  
 
Alma, Sieg en Cin, snel gaan we weer eens swingen! Alma (‘zusje’), jij gaf al het 
goede voorbeeld, ik ben dan ook erg blij met jou als paranimf. Ciska, heerlijk waren 
de hardlooprondjes samen, waarbij we al kletsend ongemerkt steeds langer liepen. 
Uiteraard ook de schaatsers van Lacustris bedankt voor de gezellige schaatslessen, 
de warme chocomel avonden, de trainingsweken in collalbo, feestjes en het IUT!  
 
Lieve Pa, Ma, Rinse, Marga, Kim, Joris en Mirian, ik prijs mij super gelukkig met een 
familie zoals jullie! Het is altijd heerlijk om weer bij jullie in het Zuiden of waar ook 
ter wereld te zijn. Pa en ma, zonder jullie had dit boekje er zeker niet gelegen en al 
helemaal niet zo mooi. Mam, het is je weer gelukt; de kaft is prachtig, bedankt! Pa, 
ook figuur 1 mag er wezen, bedankt. Het is speciaal een broer als collega te hebben 
en publiceren met je broer heeft al helemaal iets extra’s. Joris bedankt voor je 
kritische blik en al je goede tips! 
 
Erik, je hebt aardig wat geduld en begrip opgebracht de afgelopen tijd. Bedankt voor 
al je lieve steun. Nu hebben we echt tijd om samen leuke dingen te doen en zijn de 
weekenden weer voor ons! 
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Imke Veltman werd op 16 juni 1976 geboren in Hoensbroek. In 1994 behaalde zij haar 
VWO diploma aan het Sint Jans College te Hoensbroek. Aansluitend begon zij met 
de opleiding Bioprocestechnologie aan de Wageningen Universiteit, waar zij in 1999 
afstudeerde in de moleculair-cellulaire richting. Tijdens deze studie deed zij 
moleculair-biologisch onderzoek bij de vakgroep Moleculaire Biologie van de 
Wageningen Universiteit (dr. J. Carette, dr. ir. J. Wellink). Vervolgens deed zij 
immunologisch onderzoek bij de afdeling ‘Molecular Microbiology and Immunology’ 
van de Oregon Health and Sciences University te Portland (OR, VS) (dr. G. Wiens, Prof. 
dr. M. Rittenberg) en bij de afdeling Immunologie van het Erasmus MC-Universitair 
Medisch Centrum Rotterdam (dr. ir. M. Nawijn, Prof. dr. H. Savenkoul). Na haar 
afstuderen in 1999 is zij in dienst getreden als assistent in opleiding (AIO) bij de 
afdeling Antropogenetica van de Radboud Universiteit te Nijmegen (Prof. dr. A. 
Geurts van Kessel). Het onderzoek dat zij hier heeft uitgevoerd heeft geresulteerd in 
dit proefschrift. Sinds januari 2005 is zij werkzaam als postdoc op de afdeling 
Pathologie van het Erasmus MC-Universitair Medisch Centrum Rotterdam. 
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